TY  - JOUR
AU  - Toljić, Mina
AU  - Nikolić, Nađa
AU  - Joksić, Ivana
AU  - Čarkić, Jelena
AU  - Munjas, Jelena
AU  - Karadžov Orlić, Nataša
AU  - Milašin, Jelena
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5615
AB  - Altered microRNAs (miRNAs1) and cytokines expression levels are associated with several pregnancy-induced complications. We evaluated the profile of circulating miRNAs (miR-17, miR-29a and miR-181a) and proinflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-17) in women with gestational diabetes mellitus (GDM2), as well as their potential use as GDM biomarkers. The case-control study included 65 pregnant women divided into 2 groups - GDM and control. Expression levels of miRNAs in plasma samples and cytokines mRNA isolated from peripheral blood buffy coat were analyzed by quantitative real-time PCR (qPCR3). Significant miR-29a downregulation was found in GDM compared to the control group, and was even more significant after adjustments for covariates. miR-17 and miR-181a expression levels did not differ between the examined groups. Expression levels of IL-1β were significantly higher in GDM group compared to controls, while TNF-α, IL-6 and IL-17 did not show significant changes in expression between the two groups. As jugded from the ROC curve analysis, miR-29a and IL-1β had a significant capacity to discriminate between CG and GDM. Additionally, a positive correlation was established between IL-1β and TNF-α in the GDM group. GDM appeared to be associated with altered levels of miR-29a and IL-1β making them markers of this condition.
PB  - Elsevier B.V.
T2  - Journal of Reproductive Immunology
T1  - Expression of miRNAs and proinflammatory cytokines in pregnant women with gestational diabetes mellitus
VL  - 162
SP  - 104211
DO  - 10.1016/j.jri.2024.104211
ER  - 

@article{
author = "Toljić, Mina and Nikolić, Nađa and Joksić, Ivana and Čarkić, Jelena and Munjas, Jelena and Karadžov Orlić, Nataša and Milašin, Jelena",
year = "2024",
abstract = "Altered microRNAs (miRNAs1) and cytokines expression levels are associated with several pregnancy-induced complications. We evaluated the profile of circulating miRNAs (miR-17, miR-29a and miR-181a) and proinflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-17) in women with gestational diabetes mellitus (GDM2), as well as their potential use as GDM biomarkers. The case-control study included 65 pregnant women divided into 2 groups - GDM and control. Expression levels of miRNAs in plasma samples and cytokines mRNA isolated from peripheral blood buffy coat were analyzed by quantitative real-time PCR (qPCR3). Significant miR-29a downregulation was found in GDM compared to the control group, and was even more significant after adjustments for covariates. miR-17 and miR-181a expression levels did not differ between the examined groups. Expression levels of IL-1β were significantly higher in GDM group compared to controls, while TNF-α, IL-6 and IL-17 did not show significant changes in expression between the two groups. As jugded from the ROC curve analysis, miR-29a and IL-1β had a significant capacity to discriminate between CG and GDM. Additionally, a positive correlation was established between IL-1β and TNF-α in the GDM group. GDM appeared to be associated with altered levels of miR-29a and IL-1β making them markers of this condition.",
publisher = "Elsevier B.V.",
journal = "Journal of Reproductive Immunology",
title = "Expression of miRNAs and proinflammatory cytokines in pregnant women with gestational diabetes mellitus",
volume = "162",
pages = "104211",
doi = "10.1016/j.jri.2024.104211"
}

Toljić, M., Nikolić, N., Joksić, I., Čarkić, J., Munjas, J., Karadžov Orlić, N.,& Milašin, J.. (2024). Expression of miRNAs and proinflammatory cytokines in pregnant women with gestational diabetes mellitus. in Journal of Reproductive Immunology
Elsevier B.V.., 162, 104211.
https://doi.org/10.1016/j.jri.2024.104211

Toljić M, Nikolić N, Joksić I, Čarkić J, Munjas J, Karadžov Orlić N, Milašin J. Expression of miRNAs and proinflammatory cytokines in pregnant women with gestational diabetes mellitus. in Journal of Reproductive Immunology. 2024;162:104211.
doi:10.1016/j.jri.2024.104211 .

Toljić, Mina, Nikolić, Nađa, Joksić, Ivana, Čarkić, Jelena, Munjas, Jelena, Karadžov Orlić, Nataša, Milašin, Jelena, "Expression of miRNAs and proinflammatory cytokines in pregnant women with gestational diabetes mellitus" in Journal of Reproductive Immunology, 162 (2024):104211,
https://doi.org/10.1016/j.jri.2024.104211 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Karaduzovic-Hadziabdic, Kanita
AU  - Kardassis, Dimitris
AU  - Maegdefessel, Lars
AU  - Martelli, Fabio
AU  - Meerson, Ari
AU  - Munjas, Jelena
AU  - Niculescu, Loredan S.
AU  - Stoll, Monika
AU  - Magni, Paolo
AU  - Devaux, Yvan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5616
AB  - Atherosclerotic disease is a major cause of acute cardiovascular events. A deeper understanding of its underlying mechanisms will allow advancing personalized and patient-centered healthcare. Transcriptomic research has proven to be a powerful tool for unravelling the complex molecular pathways that drive atherosclerosis. However, low reproducibility of research findings and lack of standardization of procedures pose significant challenges in this field. In this review, we discuss how transcriptomic research can help in understanding the different phenotypes of the atherosclerotic plaque that contribute to the development and progression of atherosclerosis. We highlight the methodological challenges that need to be addressed to improve research outputs, and emphasize the importance of research protocols harmonization. We also discuss recent advances in transcriptomic research, including bulk or single-cell sequencing, and their added value in plaque phenotyping. Finally, we explore how integrated multiomics data and machine learning improve understanding of atherosclerosis and provide directions for future research.
PB  - Elsevier Ltd.
T2  - Journal of Molecular and Cellular Cardiology Plus
T1  - Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges
VL  - 6
SP  - 100048
DO  - 10.1016/j.jmccpl.2023.100048
ER  - 

@article{
author = "Sopić, Miron and Karaduzovic-Hadziabdic, Kanita and Kardassis, Dimitris and Maegdefessel, Lars and Martelli, Fabio and Meerson, Ari and Munjas, Jelena and Niculescu, Loredan S. and Stoll, Monika and Magni, Paolo and Devaux, Yvan",
year = "2023",
abstract = "Atherosclerotic disease is a major cause of acute cardiovascular events. A deeper understanding of its underlying mechanisms will allow advancing personalized and patient-centered healthcare. Transcriptomic research has proven to be a powerful tool for unravelling the complex molecular pathways that drive atherosclerosis. However, low reproducibility of research findings and lack of standardization of procedures pose significant challenges in this field. In this review, we discuss how transcriptomic research can help in understanding the different phenotypes of the atherosclerotic plaque that contribute to the development and progression of atherosclerosis. We highlight the methodological challenges that need to be addressed to improve research outputs, and emphasize the importance of research protocols harmonization. We also discuss recent advances in transcriptomic research, including bulk or single-cell sequencing, and their added value in plaque phenotyping. Finally, we explore how integrated multiomics data and machine learning improve understanding of atherosclerosis and provide directions for future research.",
publisher = "Elsevier Ltd.",
journal = "Journal of Molecular and Cellular Cardiology Plus",
title = "Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges",
volume = "6",
pages = "100048",
doi = "10.1016/j.jmccpl.2023.100048"
}

Sopić, M., Karaduzovic-Hadziabdic, K., Kardassis, D., Maegdefessel, L., Martelli, F., Meerson, A., Munjas, J., Niculescu, L. S., Stoll, M., Magni, P.,& Devaux, Y.. (2023). Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges. in Journal of Molecular and Cellular Cardiology Plus
Elsevier Ltd.., 6, 100048.
https://doi.org/10.1016/j.jmccpl.2023.100048

Sopić M, Karaduzovic-Hadziabdic K, Kardassis D, Maegdefessel L, Martelli F, Meerson A, Munjas J, Niculescu LS, Stoll M, Magni P, Devaux Y. Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges. in Journal of Molecular and Cellular Cardiology Plus. 2023;6:100048.
doi:10.1016/j.jmccpl.2023.100048 .

Sopić, Miron, Karaduzovic-Hadziabdic, Kanita, Kardassis, Dimitris, Maegdefessel, Lars, Martelli, Fabio, Meerson, Ari, Munjas, Jelena, Niculescu, Loredan S., Stoll, Monika, Magni, Paolo, Devaux, Yvan, "Transcriptomic research in atherosclerosis: Unravelling plaque phenotype and overcoming methodological challenges" in Journal of Molecular and Cellular Cardiology Plus, 6 (2023):100048,
https://doi.org/10.1016/j.jmccpl.2023.100048 . .

TY  - JOUR
AU  - Antonić, Tamara
AU  - Ardalić, Daniela
AU  - Vladimirov, Sandra
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Mitrović, Marija
AU  - Ivanišević, Jasmina
AU  - Gojković, Tamara
AU  - Munjas, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4957
AB  - A specific feature of dyslipidemia in pregnancy is increased high-density lipoprotein (HDL) cholesterol concentration, which is probably associated with maternal endothelium protection. However, preeclampsia is most often associated with low HDL cholesterol, and the mechanisms behind this change are scarcely explored. We aimed to investigate changes in HDL metabolism in risky pregnancies and those complicated by late-onset preeclampsia. We analyze cholesterol synthesis (cholesterol precursors: desmosterol, 7-dehydrocholesterol, and lathosterol) and absorption markers (phytosterols: campesterol and β-sitosterol) within HDL particles (NCSHDL), the activities of principal modulators of HDL cholesterol’s content, and major HDL functional proteins levels in mid and late pregnancy. On the basis of the pregnancy outcome, participants were classified into the risk group (RG) (70 women) and the preeclampsia group (PG) (20 women). HDL cholesterol was lower in PG in the second trimester compared to RG (p < 0.05) and followed by lower levels of cholesterol absorption markers (p < 0.001 for campesterolHDL and p < 0.05 for β-sitosterolHDL). Lowering of HDL cholesterol between trimesters in RG (p < 0.05) was accompanied by a decrease in HDL phytosterol content (p < 0.001), apolipoprotein A-I (apoA-I) concentration (p < 0.05), and paraoxonase 1 (PON1) (p < 0.001), lecithin–cholesterol acyltransferase (LCAT) (p < 0.05), and cholesterol ester transfer protein (CETP) activities (p < 0.05). These longitudinal changes were absent in PG. Development of late-onset preeclampsia is preceded by the appearance of lower HDL cholesterol and NCSHDL in the second trimester. We propose that reduced capacity for intestinal HDL synthesis, decreased LCAT activity, and impaired capacity for HDL-mediated cholesterol efflux could be the contributing mechanisms resulting in lower HDL cholesterol.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia
VL  - 24
IS  - 14
DO  - 10.3390/ijms241411357
ER  - 

@article{
author = "Antonić, Tamara and Ardalić, Daniela and Vladimirov, Sandra and Zeljković, Aleksandra and Vekić, Jelena and Mitrović, Marija and Ivanišević, Jasmina and Gojković, Tamara and Munjas, Jelena and Spasojević-Kalimanovska, Vesna and Miković, Željko and Stefanović, Aleksandra",
year = "2023",
abstract = "A specific feature of dyslipidemia in pregnancy is increased high-density lipoprotein (HDL) cholesterol concentration, which is probably associated with maternal endothelium protection. However, preeclampsia is most often associated with low HDL cholesterol, and the mechanisms behind this change are scarcely explored. We aimed to investigate changes in HDL metabolism in risky pregnancies and those complicated by late-onset preeclampsia. We analyze cholesterol synthesis (cholesterol precursors: desmosterol, 7-dehydrocholesterol, and lathosterol) and absorption markers (phytosterols: campesterol and β-sitosterol) within HDL particles (NCSHDL), the activities of principal modulators of HDL cholesterol’s content, and major HDL functional proteins levels in mid and late pregnancy. On the basis of the pregnancy outcome, participants were classified into the risk group (RG) (70 women) and the preeclampsia group (PG) (20 women). HDL cholesterol was lower in PG in the second trimester compared to RG (p < 0.05) and followed by lower levels of cholesterol absorption markers (p < 0.001 for campesterolHDL and p < 0.05 for β-sitosterolHDL). Lowering of HDL cholesterol between trimesters in RG (p < 0.05) was accompanied by a decrease in HDL phytosterol content (p < 0.001), apolipoprotein A-I (apoA-I) concentration (p < 0.05), and paraoxonase 1 (PON1) (p < 0.001), lecithin–cholesterol acyltransferase (LCAT) (p < 0.05), and cholesterol ester transfer protein (CETP) activities (p < 0.05). These longitudinal changes were absent in PG. Development of late-onset preeclampsia is preceded by the appearance of lower HDL cholesterol and NCSHDL in the second trimester. We propose that reduced capacity for intestinal HDL synthesis, decreased LCAT activity, and impaired capacity for HDL-mediated cholesterol efflux could be the contributing mechanisms resulting in lower HDL cholesterol.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia",
volume = "24",
number = "14",
doi = "10.3390/ijms241411357"
}

Antonić, T., Ardalić, D., Vladimirov, S., Zeljković, A., Vekić, J., Mitrović, M., Ivanišević, J., Gojković, T., Munjas, J., Spasojević-Kalimanovska, V., Miković, Ž.,& Stefanović, A.. (2023). Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia. in International Journal of Molecular Sciences
MDPI., 24(14).
https://doi.org/10.3390/ijms241411357

Antonić T, Ardalić D, Vladimirov S, Zeljković A, Vekić J, Mitrović M, Ivanišević J, Gojković T, Munjas J, Spasojević-Kalimanovska V, Miković Ž, Stefanović A. Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia. in International Journal of Molecular Sciences. 2023;24(14).
doi:10.3390/ijms241411357 .

Antonić, Tamara, Ardalić, Daniela, Vladimirov, Sandra, Zeljković, Aleksandra, Vekić, Jelena, Mitrović, Marija, Ivanišević, Jasmina, Gojković, Tamara, Munjas, Jelena, Spasojević-Kalimanovska, Vesna, Miković, Željko, Stefanović, Aleksandra, "Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia" in International Journal of Molecular Sciences, 24, no. 14 (2023),
https://doi.org/10.3390/ijms241411357 . .

TY  - JOUR
AU  - Ivanišević, Jasmina
AU  - Ardalić, Daniela
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Antonić, Tamara
AU  - Munjas, Jelena
AU  - Stefanović, Aleksandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4637
AB  - The 1st trimester of pregnancy is accompanied with changes in different biochemical and
hematological parameters. Analyses scheduled to be performed in the 1st trimester are complete
blood count, blood group, Rh factor and the double test. Many experts also suggest the
determination of lipid status parameters as a routine analysis in the early pregnancy. Reliable data
about maternal and fetal health can be obtained by the assessment of the above-mentioned
parameters. They may be helpful in assessing the risk for pregnancy complication development
and/or perinatal adverse outcomes.
AB  - Prvi trimestar trudnoće praćen je promenama različitih biohemijskih i hematoloških
parametara. Analize koje se rade u 1. trimestru su kompletna krvna slika, krvna grupa, Rh faktor
i tzv. „double“ test. Mnogi stručnjaci predlažu određivanje parametara lipidnog statusa kao
rutinsku analizu u ranoj trudnoći. Procenom gore navedenih parametara mogu se dobiti pouzdani
podaci o zdravlju majke i fetusa, a mogu da posluže i za procenu rizika za razvoj komplikacija u
trudnoći i/ili perinatalnih neželjenih ishoda.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Biochemical and hematological parameters in the  1 st  trimester of pregnancy
T1  - Biohemijski i hematološki parametri u prvom  trimestru trudnoće
VL  - 73
IS  - 1
SP  - 62
EP  - 73
DO  - 10.5937/arhfarm73-41999
ER  - 

@article{
author = "Ivanišević, Jasmina and Ardalić, Daniela and Zeljković, Aleksandra and Vekić, Jelena and Gojković, Tamara and Vladimirov, Sandra and Antonić, Tamara and Munjas, Jelena and Stefanović, Aleksandra",
year = "2023",
abstract = "The 1st trimester of pregnancy is accompanied with changes in different biochemical and
hematological parameters. Analyses scheduled to be performed in the 1st trimester are complete
blood count, blood group, Rh factor and the double test. Many experts also suggest the
determination of lipid status parameters as a routine analysis in the early pregnancy. Reliable data
about maternal and fetal health can be obtained by the assessment of the above-mentioned
parameters. They may be helpful in assessing the risk for pregnancy complication development
and/or perinatal adverse outcomes., Prvi trimestar trudnoće praćen je promenama različitih biohemijskih i hematoloških
parametara. Analize koje se rade u 1. trimestru su kompletna krvna slika, krvna grupa, Rh faktor
i tzv. „double“ test. Mnogi stručnjaci predlažu određivanje parametara lipidnog statusa kao
rutinsku analizu u ranoj trudnoći. Procenom gore navedenih parametara mogu se dobiti pouzdani
podaci o zdravlju majke i fetusa, a mogu da posluže i za procenu rizika za razvoj komplikacija u
trudnoći i/ili perinatalnih neželjenih ishoda.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Biochemical and hematological parameters in the  1 st  trimester of pregnancy, Biohemijski i hematološki parametri u prvom  trimestru trudnoće",
volume = "73",
number = "1",
pages = "62-73",
doi = "10.5937/arhfarm73-41999"
}

Ivanišević, J., Ardalić, D., Zeljković, A., Vekić, J., Gojković, T., Vladimirov, S., Antonić, T., Munjas, J.,& Stefanović, A.. (2023). Biochemical and hematological parameters in the  1 st  trimester of pregnancy. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 73(1), 62-73.
https://doi.org/10.5937/arhfarm73-41999

Ivanišević J, Ardalić D, Zeljković A, Vekić J, Gojković T, Vladimirov S, Antonić T, Munjas J, Stefanović A. Biochemical and hematological parameters in the  1 st  trimester of pregnancy. in Arhiv za farmaciju. 2023;73(1):62-73.
doi:10.5937/arhfarm73-41999 .

Ivanišević, Jasmina, Ardalić, Daniela, Zeljković, Aleksandra, Vekić, Jelena, Gojković, Tamara, Vladimirov, Sandra, Antonić, Tamara, Munjas, Jelena, Stefanović, Aleksandra, "Biochemical and hematological parameters in the  1 st  trimester of pregnancy" in Arhiv za farmaciju, 73, no. 1 (2023):62-73,
https://doi.org/10.5937/arhfarm73-41999 . .

TY  - JOUR
AU  - Petković, Aleksa
AU  - Erceg, Sanja
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Vladimirov, Sandra
AU  - Davidović, Aleksandar
AU  - Vukmirović, Luka
AU  - Milanov, Marko
AU  - Cvijanović, Dane
AU  - Mitić, Tijana
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4955
AB  - Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
PB  - MDPI
T2  - Cells
T1  - LncRNAs as Regulators of Atherosclerotic Plaque Stability
VL  - 12
IS  - 14
DO  - 10.3390/cells12141832
ER  - 

@article{
author = "Petković, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninić, Ana and Vladimirov, Sandra and Davidović, Aleksandar and Vukmirović, Luka and Milanov, Marko and Cvijanović, Dane and Mitić, Tijana and Sopić, Miron",
year = "2023",
abstract = "Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.",
publisher = "MDPI",
journal = "Cells",
title = "LncRNAs as Regulators of Atherosclerotic Plaque Stability",
volume = "12",
number = "14",
doi = "10.3390/cells12141832"
}

Petković, A., Erceg, S., Munjas, J., Ninić, A., Vladimirov, S., Davidović, A., Vukmirović, L., Milanov, M., Cvijanović, D., Mitić, T.,& Sopić, M.. (2023). LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells
MDPI., 12(14).
https://doi.org/10.3390/cells12141832

Petković A, Erceg S, Munjas J, Ninić A, Vladimirov S, Davidović A, Vukmirović L, Milanov M, Cvijanović D, Mitić T, Sopić M. LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells. 2023;12(14).
doi:10.3390/cells12141832 .

Petković, Aleksa, Erceg, Sanja, Munjas, Jelena, Ninić, Ana, Vladimirov, Sandra, Davidović, Aleksandar, Vukmirović, Luka, Milanov, Marko, Cvijanović, Dane, Mitić, Tijana, Sopić, Miron, "LncRNAs as Regulators of Atherosclerotic Plaque Stability" in Cells, 12, no. 14 (2023),
https://doi.org/10.3390/cells12141832 . .

TY  - JOUR
AU  - Rajkov, Branislava
AU  - Zdravković, Marija
AU  - Ninić, Ana
AU  - Brajković, Milica
AU  - Klašnja, Slobodan
AU  - Gardijan, Vera
AU  - Memon, Lidija
AU  - Munjas, Jelena
AU  - Mihajlović, Marija
AU  - Spasojević-Kalimanovska, Vesna
AU  - Radosavljević, Vojislav
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4551
AB  - Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.
PB  - Springer Nature
T2  - Sleep and Breathing
T1  - Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus
DO  - 10.1007/s11325-023-02809-0
ER  - 

@article{
author = "Rajkov, Branislava and Zdravković, Marija and Ninić, Ana and Brajković, Milica and Klašnja, Slobodan and Gardijan, Vera and Memon, Lidija and Munjas, Jelena and Mihajlović, Marija and Spasojević-Kalimanovska, Vesna and Radosavljević, Vojislav and Sopić, Miron",
year = "2023",
abstract = "Purpose: Obstructive sleep apnea (OSA) is characterised by increased systemic inflammation, and is often accompanied with type 2 diabetes mellitus (T2DM) and cardiovascular disease. The aim of this investigation was to evaluate gene expression of resistin, its receptor CAP1 and CD36 as the indicators of the inflammatory changes in PBMCs in relation to the severity of OSA, and the presence of type 2 diabetes mellitus (T2DM) in OSA. Methods: Severity of OSA was defined by the apnea/hypopnea index (AHI): AHI < 30: mild to moderate OSA (MM-OSA), AHI ≥ 30: severe OSA (S-OSA). Presence of T2DM was captured: OSA with T2DM (OSA + T2DM), OSA without T2DM (OSA-T2DM). PBMC resistin, CAP1, and CD36 mRNA were determined by real-time PCR. Results: Resistin mRNA was significantly upregulated in S-OSA (N = 54) compared to the MM-OSA (N = 52, P = 0.043); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.302; P = 0.166, respectively). Resistin mRNA was significantly upregulated in OSA + T2DM (N = 29) compared to the OSA-T2DM (N = 77, P = 0.029); CAP1 and CD36 mRNA levels did not differ between the groups (P = 0.662; P = 0.108, respectively). AHI and T2DM were independent predictors of resistin mRNA above the 75th percentile (OR = 3.717 [1.152–11.991]; OR = 3.261 [1.000–10.630], P = 0.042 respectively). Conclusion: Resistin gene upregulation in S-OSA indicates its possible contribution to increased inflammation in S-OSA and makes it a possible marker of the disease severity. Resistin gene upregulation in OSA + T2DM suggests that a joint effect of these two comorbidities may have a major contribution to increased inflammation and complications that arise from this state.",
publisher = "Springer Nature",
journal = "Sleep and Breathing",
title = "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus",
doi = "10.1007/s11325-023-02809-0"
}

Rajkov, B., Zdravković, M., Ninić, A., Brajković, M., Klašnja, S., Gardijan, V., Memon, L., Munjas, J., Mihajlović, M., Spasojević-Kalimanovska, V., Radosavljević, V.,& Sopić, M.. (2023). Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing
Springer Nature..
https://doi.org/10.1007/s11325-023-02809-0

Rajkov B, Zdravković M, Ninić A, Brajković M, Klašnja S, Gardijan V, Memon L, Munjas J, Mihajlović M, Spasojević-Kalimanovska V, Radosavljević V, Sopić M. Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus. in Sleep and Breathing. 2023;.
doi:10.1007/s11325-023-02809-0 .

Rajkov, Branislava, Zdravković, Marija, Ninić, Ana, Brajković, Milica, Klašnja, Slobodan, Gardijan, Vera, Memon, Lidija, Munjas, Jelena, Mihajlović, Marija, Spasojević-Kalimanovska, Vesna, Radosavljević, Vojislav, Sopić, Miron, "Upregulation of peripheral blood mononuclear cells resistin gene expression in severe obstructive sleep apnea and obstructive sleep apnea with coexisting type 2 diabetes mellitus" in Sleep and Breathing (2023),
https://doi.org/10.1007/s11325-023-02809-0 . .

TY  - JOUR
AU  - Klisić, Aleksandra
AU  - Radoman Vujačić, Irena
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Kotur-Stevuljević, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4247
AB  - In parallel with the rapid growth of obesity, there is also an increase in the prevalence of type 2 diabetes mellitus (T2D) worldwide. Due to its compli- cations, cardiovascular diseases are the leading cause of death in those patients. In the last two decades, special attention has been given to ox- idative stress and inflammation, as the underlying mechanisms related to T2D occurrence and progression. Moreover, micro-ribonucleic acids (miRNAs) as new genetic biomarkers take an important place in the investigation of different metabolic pathways of insulin signaling. In this review article, we discuss microRNA modulation with oxidative stress and inflammation in pa- tients with T2D. Better insight into the novel potential therapeutic targets for treatment of diabetes and its complications is of utmost importance for public health.
PB  - Termedia Publishing House Ltd.
T2  - Archives of Medical Science
T1  - Micro-ribonucleic acid modulation with oxidative stress and inflammation in patients with type 2 diabetes mellitus - a review article
VL  - 18
IS  - 4
SP  - 870
EP  - 880
DO  - 10.5114/aoms/146796
ER  - 

@article{
author = "Klisić, Aleksandra and Radoman Vujačić, Irena and Munjas, Jelena and Ninić, Ana and Kotur-Stevuljević, Jelena",
year = "2022",
abstract = "In parallel with the rapid growth of obesity, there is also an increase in the prevalence of type 2 diabetes mellitus (T2D) worldwide. Due to its compli- cations, cardiovascular diseases are the leading cause of death in those patients. In the last two decades, special attention has been given to ox- idative stress and inflammation, as the underlying mechanisms related to T2D occurrence and progression. Moreover, micro-ribonucleic acids (miRNAs) as new genetic biomarkers take an important place in the investigation of different metabolic pathways of insulin signaling. In this review article, we discuss microRNA modulation with oxidative stress and inflammation in pa- tients with T2D. Better insight into the novel potential therapeutic targets for treatment of diabetes and its complications is of utmost importance for public health.",
publisher = "Termedia Publishing House Ltd.",
journal = "Archives of Medical Science",
title = "Micro-ribonucleic acid modulation with oxidative stress and inflammation in patients with type 2 diabetes mellitus - a review article",
volume = "18",
number = "4",
pages = "870-880",
doi = "10.5114/aoms/146796"
}

Klisić, A., Radoman Vujačić, I., Munjas, J., Ninić, A.,& Kotur-Stevuljević, J.. (2022). Micro-ribonucleic acid modulation with oxidative stress and inflammation in patients with type 2 diabetes mellitus - a review article. in Archives of Medical Science
Termedia Publishing House Ltd.., 18(4), 870-880.
https://doi.org/10.5114/aoms/146796

Klisić A, Radoman Vujačić I, Munjas J, Ninić A, Kotur-Stevuljević J. Micro-ribonucleic acid modulation with oxidative stress and inflammation in patients with type 2 diabetes mellitus - a review article. in Archives of Medical Science. 2022;18(4):870-880.
doi:10.5114/aoms/146796 .

Klisić, Aleksandra, Radoman Vujačić, Irena, Munjas, Jelena, Ninić, Ana, Kotur-Stevuljević, Jelena, "Micro-ribonucleic acid modulation with oxidative stress and inflammation in patients with type 2 diabetes mellitus - a review article" in Archives of Medical Science, 18, no. 4 (2022):870-880,
https://doi.org/10.5114/aoms/146796 . .

TY  - JOUR
AU  - Sopić, Miron
AU  - Ninić, Ana
AU  - Ostanek, Barbara
AU  - Bojanin, Dragana
AU  - Milenković, Tatjana
AU  - Munjas, Jelena
AU  - Mihajlović, Marija
AU  - Vekić, Jelena
AU  - Marc, Janja
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4255
AB  - Background: Type 1 diabetes mellitus (T1DM) is one of the
most common endocrine diseases in children. T-cell autore-
activity toward b-cells is controlled by significant changes in
metabolism of T cells. Mammalian target of rapamycin
(mTOR) is an important intracellular regulator of metabolism
and cell growth. MAPK/MAK/MRK overlapping kinase 1
(MOK1) is one of the less known regulators of mTOR. We
sought to investigate if MOK1 and mTOR mRNA levels in
peripheral blood mononuclear cells (PBMCs) of T1DM pedi-
atric patients are different compared to healthy subjects.
Methods: This study included 172 adolescents with T1DM
and 36 healthy adolescent volunteers designated for control
group (CG). MOK1 and mTOR mRNA levels were deter-
mined in PBMCs by qPCR.
Results: T1DM patients have significant downregulation of
MOK1 mRNA levels in PBMCs compared CG (P=0.018),
while there was no significant difference in mTOR mRNA
levels (P=0.891). Furthermore, in T1DM patients, MOK1
significantly correlated with age, triglycerides and mTOR,
while mTOR correlated significantly with BMI and systolic
blood pressure. Overweight T1DM subjects had significantly
lower MOK1 (P=0.034) and mTOR (P=0.017) mRNA
levels, together with significantly higher levels of systolic
blood pressure (P<0.001), total cholesterol (P=0.001),
LDL-cholesterol (P=0.001) and CRP (P<0.001). Multi-
variate analysis showed that MOK1 was independently
negatively associated with T1DM when adjusted for sex, age, HDL-C and CRP (OR=0.417 (95%CI: 0.175–0.997),
p=0.049).
Conclusions: Our study demonstrated for the first time that
T1DM is associated with MOK1 downregulation. In addition,
downregulation of both mTOR and MOK1 gene expressions
was associated with cardiovascular risk factors in overweight
T1DM patients.
AB  - Uvod: Dijabetes melitus tip 1 (T1DM) jedno je od najčešćih endokrinih oboljenja kod dece. Autoreaktivnost T-ćelija prema b-ćelijama kontroliše se značajnim promenama u metabolizmu T ćelija. Cilj delovanja rapamicina kod sisara je važan unutarćelijski regulator metabolizma i rasta ćelija. MAPK/MAK/MRK preklapajuće kinaze koja se preklapa (MOK1) jedan je od manje poznatih regulatora mTOR-a. Cilj istraživanja je bio da se ispita da li su nivoi iRNK MOK1 i mTOR u mononuklearnim ćelijama periferne krvi različiti kod pedijatrijskih pacijenata sa T1DM u odnosu na zdrave ispitanike. Metode: Ovo istraživanje je obuhvatilo 172 adolescenta sa T1DM i 36 zdravih adolescenata dobrovoljaca koji su činili kontrolnu grupu (CG). Nivoi MOK1 i mTOR mRNA određeni su u PBMC-ima pomoću qPCR-a. Rezultati: Pacijenti sa T1DM imali su značajno niže nivoe iRNK MOK1 u PBMC u odnosu na CG, dok razlike u nivoima iRNK mTOR nisu bile značajne (P = 0,891). Štaviše, kod pacijenata sa T1DM, MOK1 je značajno korelirao sa godinama, trigliceri dima i mTOR, dok je mTOR značajno korelirao sa BMI i sistolnim krvnim pritiskom. Ispitanici sa prekomernom težinom T1DM imali su značajno niže nivoe iRNK MOK1 (P = 0,034) i mTOR (P = 0,017), zajedno sa značajno većim nivoima sistolnog krvnog pritiska (P <0,001), ukupnog holesterola (P = 0,001), LDL-holesterola (P = 0,001) i CRP (P <0,001). Multivarijantna analiza je pokazala da je MOK1 nezavisno negativno povezan sa T1DM kada je prilagođen polu, starosti, HDL-C i CRP (OR = 0,417 (95%CI: 0,175-0,997), p = 0,049). Zaključak: Naša studija je prva koja je pokazala da je T1DM udružen sa nishodnom regulacijom MOK1. Pored toga, snižena regulacija ekspresije gena mTOR i MOK1 bila je povezana sa kardiovaskularnim faktorima rizika kod pacije nata sa T1DM sa prekomernom težinom.
PB  - Beograd : Društvo medicinskih biohemičara Srbije
T2  - Journal of Medical Biochemistry
T1  - Downregulation of MAPK/MAK/MRK overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus
T1  - Nishodna regulacija MAPK/MAK/MRK preklapajuće kinaze u mononuklearnim ćelijama periferne krvi pedijatrijskih pacijenata sa tip1 diiabetes mellitus-om
VL  - 41
IS  - 3
SP  - 282
EP  - 289
DO  - 10.5937/jomb0-33220
ER  - 

@article{
author = "Sopić, Miron and Ninić, Ana and Ostanek, Barbara and Bojanin, Dragana and Milenković, Tatjana and Munjas, Jelena and Mihajlović, Marija and Vekić, Jelena and Marc, Janja and Spasojević-Kalimanovska, Vesna",
year = "2022",
abstract = "Background: Type 1 diabetes mellitus (T1DM) is one of the
most common endocrine diseases in children. T-cell autore-
activity toward b-cells is controlled by significant changes in
metabolism of T cells. Mammalian target of rapamycin
(mTOR) is an important intracellular regulator of metabolism
and cell growth. MAPK/MAK/MRK overlapping kinase 1
(MOK1) is one of the less known regulators of mTOR. We
sought to investigate if MOK1 and mTOR mRNA levels in
peripheral blood mononuclear cells (PBMCs) of T1DM pedi-
atric patients are different compared to healthy subjects.
Methods: This study included 172 adolescents with T1DM
and 36 healthy adolescent volunteers designated for control
group (CG). MOK1 and mTOR mRNA levels were deter-
mined in PBMCs by qPCR.
Results: T1DM patients have significant downregulation of
MOK1 mRNA levels in PBMCs compared CG (P=0.018),
while there was no significant difference in mTOR mRNA
levels (P=0.891). Furthermore, in T1DM patients, MOK1
significantly correlated with age, triglycerides and mTOR,
while mTOR correlated significantly with BMI and systolic
blood pressure. Overweight T1DM subjects had significantly
lower MOK1 (P=0.034) and mTOR (P=0.017) mRNA
levels, together with significantly higher levels of systolic
blood pressure (P<0.001), total cholesterol (P=0.001),
LDL-cholesterol (P=0.001) and CRP (P<0.001). Multi-
variate analysis showed that MOK1 was independently
negatively associated with T1DM when adjusted for sex, age, HDL-C and CRP (OR=0.417 (95%CI: 0.175–0.997),
p=0.049).
Conclusions: Our study demonstrated for the first time that
T1DM is associated with MOK1 downregulation. In addition,
downregulation of both mTOR and MOK1 gene expressions
was associated with cardiovascular risk factors in overweight
T1DM patients., Uvod: Dijabetes melitus tip 1 (T1DM) jedno je od najčešćih endokrinih oboljenja kod dece. Autoreaktivnost T-ćelija prema b-ćelijama kontroliše se značajnim promenama u metabolizmu T ćelija. Cilj delovanja rapamicina kod sisara je važan unutarćelijski regulator metabolizma i rasta ćelija. MAPK/MAK/MRK preklapajuće kinaze koja se preklapa (MOK1) jedan je od manje poznatih regulatora mTOR-a. Cilj istraživanja je bio da se ispita da li su nivoi iRNK MOK1 i mTOR u mononuklearnim ćelijama periferne krvi različiti kod pedijatrijskih pacijenata sa T1DM u odnosu na zdrave ispitanike. Metode: Ovo istraživanje je obuhvatilo 172 adolescenta sa T1DM i 36 zdravih adolescenata dobrovoljaca koji su činili kontrolnu grupu (CG). Nivoi MOK1 i mTOR mRNA određeni su u PBMC-ima pomoću qPCR-a. Rezultati: Pacijenti sa T1DM imali su značajno niže nivoe iRNK MOK1 u PBMC u odnosu na CG, dok razlike u nivoima iRNK mTOR nisu bile značajne (P = 0,891). Štaviše, kod pacijenata sa T1DM, MOK1 je značajno korelirao sa godinama, trigliceri dima i mTOR, dok je mTOR značajno korelirao sa BMI i sistolnim krvnim pritiskom. Ispitanici sa prekomernom težinom T1DM imali su značajno niže nivoe iRNK MOK1 (P = 0,034) i mTOR (P = 0,017), zajedno sa značajno većim nivoima sistolnog krvnog pritiska (P <0,001), ukupnog holesterola (P = 0,001), LDL-holesterola (P = 0,001) i CRP (P <0,001). Multivarijantna analiza je pokazala da je MOK1 nezavisno negativno povezan sa T1DM kada je prilagođen polu, starosti, HDL-C i CRP (OR = 0,417 (95%CI: 0,175-0,997), p = 0,049). Zaključak: Naša studija je prva koja je pokazala da je T1DM udružen sa nishodnom regulacijom MOK1. Pored toga, snižena regulacija ekspresije gena mTOR i MOK1 bila je povezana sa kardiovaskularnim faktorima rizika kod pacije nata sa T1DM sa prekomernom težinom.",
publisher = "Beograd : Društvo medicinskih biohemičara Srbije",
journal = "Journal of Medical Biochemistry",
title = "Downregulation of MAPK/MAK/MRK overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus, Nishodna regulacija MAPK/MAK/MRK preklapajuće kinaze u mononuklearnim ćelijama periferne krvi pedijatrijskih pacijenata sa tip1 diiabetes mellitus-om",
volume = "41",
number = "3",
pages = "282-289",
doi = "10.5937/jomb0-33220"
}

Sopić, M., Ninić, A., Ostanek, B., Bojanin, D., Milenković, T., Munjas, J., Mihajlović, M., Vekić, J., Marc, J.,& Spasojević-Kalimanovska, V.. (2022). Downregulation of MAPK/MAK/MRK overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus. in Journal of Medical Biochemistry
Beograd : Društvo medicinskih biohemičara Srbije., 41(3), 282-289.
https://doi.org/10.5937/jomb0-33220

Sopić M, Ninić A, Ostanek B, Bojanin D, Milenković T, Munjas J, Mihajlović M, Vekić J, Marc J, Spasojević-Kalimanovska V. Downregulation of MAPK/MAK/MRK overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus. in Journal of Medical Biochemistry. 2022;41(3):282-289.
doi:10.5937/jomb0-33220 .

Sopić, Miron, Ninić, Ana, Ostanek, Barbara, Bojanin, Dragana, Milenković, Tatjana, Munjas, Jelena, Mihajlović, Marija, Vekić, Jelena, Marc, Janja, Spasojević-Kalimanovska, Vesna, "Downregulation of MAPK/MAK/MRK overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus" in Journal of Medical Biochemistry, 41, no. 3 (2022):282-289,
https://doi.org/10.5937/jomb0-33220 . .

TY  - JOUR
AU  - Petković, Aleksa
AU  - Erceg, Sanja
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Sopić, Miron
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4186
AB  - Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis
involves an interplay of different pathological mechanisms, such as progressive inflammation,
abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological
phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries,
creating an ischemic environment for the heart muscle, which finally leads to clinical
complications, such as acute myocardial infarction. Currently, there are no biomarkers that could
predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional
non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in
the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long
non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in
extracellular fluids can originate from different cells, circulating ncRNAs are being intensively
investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following
paper, we provide current insights into potential molecular mechanisms by which miRNAs and
lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in
diagnosis and prognosis of disease.
AB  - Koronarna arterijska bolest (KAB) predstavlja vodeći uzrok smrtnosti širom sveta. Osnovni patološki proces koji karakteriše KAB je ateroskleroza, koju odlikuju različiti patofiziološki mehanizmi kao što su progresivna inflamacija, poremećen metabolizam lipida, oksidativni stres, itd. Aterosklerotski plak sužava lumen koronarnih arterija, što dovodi do nastanka ishemijskih promena na srčanom mišiću, posledično dovodeći do kliničkih komplikacija ove bolesti, kao što je akutni infarkt miokarda. Trenutno ne postoje biomarkeri koji bi mogli da predvide sudbinu aterosklerotskog plaka, kao ni razvoj akutnih koronarnih događaja ili razvoj velikih uznapredovalih kardiovaskularnih događaja. Mnogobrojne vrste nekodirajućih RNK molekula utiču na osnovne ćelijske funkcije i kao takve igraju ulogu u nastanku i progresiji KAB. Do sada su od svih vrsta nekodirajućih RNK-a najviše istražene mikro RNK-a (miRNK) i dugolančane nekodirajuće RNK-a (dnkRNK). Uzimajući u obzir da nekodirajuće RNK-a dospevaju u ekstracelularnu tečnost iz različitih ćelija, trenutno se veliki napori ulažu u ispitivanje mogućnosti upotrebe cirkulišuih nekodirajućih RNK-a kao potencijalnih biomarkera u dijagnostici i prognostici KAB. U ovom naučno-istraživačkom članku sažećemo trenutna saznanja o molekularnim mehanizmima preko kojih miRNK i dnkRNK doprinose razvoju KAB, kao i o potencijalnoj primeni ovih molekula kao budućih biomarkera u dijagnozi i prognozi ove bolesti.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Circulating non-coding RNAs as biomarkers in coronary artery disease
T1  - Cirkulišuće nekodirajuće RNK kao biomarkeri u koronarnoj arterijskoj bolesti
VL  - 72
IS  - 2
SP  - 149
EP  - 165
DO  - 10.5937/arhfarm72-36166
ER  - 

@article{
author = "Petković, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninić, Ana and Sopić, Miron",
year = "2022",
abstract = "Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis
involves an interplay of different pathological mechanisms, such as progressive inflammation,
abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological
phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries,
creating an ischemic environment for the heart muscle, which finally leads to clinical
complications, such as acute myocardial infarction. Currently, there are no biomarkers that could
predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional
non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in
the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long
non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in
extracellular fluids can originate from different cells, circulating ncRNAs are being intensively
investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following
paper, we provide current insights into potential molecular mechanisms by which miRNAs and
lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in
diagnosis and prognosis of disease., Koronarna arterijska bolest (KAB) predstavlja vodeći uzrok smrtnosti širom sveta. Osnovni patološki proces koji karakteriše KAB je ateroskleroza, koju odlikuju različiti patofiziološki mehanizmi kao što su progresivna inflamacija, poremećen metabolizam lipida, oksidativni stres, itd. Aterosklerotski plak sužava lumen koronarnih arterija, što dovodi do nastanka ishemijskih promena na srčanom mišiću, posledično dovodeći do kliničkih komplikacija ove bolesti, kao što je akutni infarkt miokarda. Trenutno ne postoje biomarkeri koji bi mogli da predvide sudbinu aterosklerotskog plaka, kao ni razvoj akutnih koronarnih događaja ili razvoj velikih uznapredovalih kardiovaskularnih događaja. Mnogobrojne vrste nekodirajućih RNK molekula utiču na osnovne ćelijske funkcije i kao takve igraju ulogu u nastanku i progresiji KAB. Do sada su od svih vrsta nekodirajućih RNK-a najviše istražene mikro RNK-a (miRNK) i dugolančane nekodirajuće RNK-a (dnkRNK). Uzimajući u obzir da nekodirajuće RNK-a dospevaju u ekstracelularnu tečnost iz različitih ćelija, trenutno se veliki napori ulažu u ispitivanje mogućnosti upotrebe cirkulišuih nekodirajućih RNK-a kao potencijalnih biomarkera u dijagnostici i prognostici KAB. U ovom naučno-istraživačkom članku sažećemo trenutna saznanja o molekularnim mehanizmima preko kojih miRNK i dnkRNK doprinose razvoju KAB, kao i o potencijalnoj primeni ovih molekula kao budućih biomarkera u dijagnozi i prognozi ove bolesti.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Circulating non-coding RNAs as biomarkers in coronary artery disease, Cirkulišuće nekodirajuće RNK kao biomarkeri u koronarnoj arterijskoj bolesti",
volume = "72",
number = "2",
pages = "149-165",
doi = "10.5937/arhfarm72-36166"
}

Petković, A., Erceg, S., Munjas, J., Ninić, A.,& Sopić, M.. (2022). Circulating non-coding RNAs as biomarkers in coronary artery disease. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 72(2), 149-165.
https://doi.org/10.5937/arhfarm72-36166

Petković A, Erceg S, Munjas J, Ninić A, Sopić M. Circulating non-coding RNAs as biomarkers in coronary artery disease. in Arhiv za farmaciju. 2022;72(2):149-165.
doi:10.5937/arhfarm72-36166 .

Petković, Aleksa, Erceg, Sanja, Munjas, Jelena, Ninić, Ana, Sopić, Miron, "Circulating non-coding RNAs as biomarkers in coronary artery disease" in Arhiv za farmaciju, 72, no. 2 (2022):149-165,
https://doi.org/10.5937/arhfarm72-36166 . .

TY  - CONF
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Ninić, Ana
AU  - Dobričić, Marija
AU  - Ležajić, Višnja
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4482
AB  - MicroRNAs (miRNAs) are small, 22-24 nucleotides long, noncoding RNAs that act as
pivotal posttranscriptional regulators in various biological processes. Interaction of miRNAs
with their target RNAs in most cases leads to the suppression of gene expression, by
promoting degradation of RNAs or inhibiting translation. These interactions mainly occur
with 3′ untranslated regions (UTR), but can also occur with 5′ UTR or with the coding part of
the target RNA molecule. It is estimated that miRNAs regulate more than 30–60% of protein
coding genes in the human genome. Oxidative stress refers to an imbalance between reactive
oxygen species (ROS) generation and body's capability to detoxify the reactive mediators or
to fix the relating damage. ROS can regulate miRNA transcription, maturation, and function.
ROS directly modulate the activity of vital proteins that control posttranscriptional events in
the biogenesis of miRNAs (Di George critical region-8 protein; Dicer). A certain group of
transcription factors involved in the regulation of miRNA expression is upregulated under
oxidative stress and directly activates the transcription of a subset of miRNAs. ROS have
been directly implicated in epigenetic alternations such as DNA methylation and histone
modifications that control specific microRNA transcription (1). On the other hand, miRNAs
may in turn modulate the redox signalling pathways, altering their integrity, stability, and
functionality, thus contributing to the pathogenesis of multiple diseases: cancer,
neurodegenerative diseases, diabetes mellitus (2), ROS-related cardiac diseases, including
myocardial infarction, ischemia/reperfusion injury, cardiac hypertrophy and heart failure,
and are also considered as potential therapeutic targets and novel diagnostic tools.
AB  - MikroRNK (miRNK) predstavljaju male, nekodirajuće RNK, dužine 22-24 nukleotida,
koje regulišu ekspresiju gena na post-transkripcionom nivou. Interakcija miRNK sa ciljnim
informacionim RNK (iRNK) u većini slučajeva dovodi do supresije ekspresije gena,
degradacijom ciljne iRNK ili inhibicijom translacije. Ove interakcije se dešavaju na
nekodirajućim 3’krajevima iRNK, ali mogu da se dese i na 5’ kraju ili čak na kodirajućem
regionu ciljne iRNK. Smatra se da na ovaj način, u humanom genomu, miRNK kontrolišu oko
30-60% gena koji kodiraju proteine. Oksidativni stres je stanje u kome postoji neravnoteža
između stvaranja reaktivnih vrsta kiseonika (slobodni radikali, ROS) i njihovog neutralisanja
od strane antioksidativne zaštite organizma. Pokazano je da ROS mogu da utiču na procese
transkripcije i sazrevanja miRNK kao i na njihovu funkciju. ROS direktno modulišu aktivnost
glavnih proteina koji učestvuju u post-transkripcionoj obradi u procesu biogeneze miRNK
(Di George critical region-8 protein i Dicer). Pod uticajem oksidativnog stresa može se
aktivirati transkripcija određenih familija miRNK, dejstvom na transkripcione faktore koji
učetvuju u tom procesu. Takođe, ROS utiču na epigenetske mehanizme regulacije ekspresije
miRNK, kao što su DNK metilacija i modifikacija histona (1). Sa druge strane, miRNK mogu da
utiču na aktivnost redoks signalnih puteva, menjajući njihovo funkcionisanje. Na taj način
miRNK doprinose patogenezi mnogih bolesti kao što su: različite vrste kancera,
neurodegenerativne bolesti, dijabetes melitus (2), bolesti srca, uključujući infarkt miokarda,
povredu nastalu ishemijom/reperfuzijom, srčanu hipertrofiju i srčanu insuficijenciju.
Takođe, miRNK se razmatraju kao potencijalni dijagnostički markeri i novi terapijski ciljevi.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - The role of microRNAs in oxidative stress regulation
T1  - Uloga mikroRNK u regulaciji oksidativnog stresa
VL  - 72
IS  - 4 suplement
SP  - S152
EP  - S153
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4482
ER  - 

@conference{
author = "Munjas, Jelena and Sopić, Miron and Ninić, Ana and Dobričić, Marija and Ležajić, Višnja",
year = "2022",
abstract = "MicroRNAs (miRNAs) are small, 22-24 nucleotides long, noncoding RNAs that act as
pivotal posttranscriptional regulators in various biological processes. Interaction of miRNAs
with their target RNAs in most cases leads to the suppression of gene expression, by
promoting degradation of RNAs or inhibiting translation. These interactions mainly occur
with 3′ untranslated regions (UTR), but can also occur with 5′ UTR or with the coding part of
the target RNA molecule. It is estimated that miRNAs regulate more than 30–60% of protein
coding genes in the human genome. Oxidative stress refers to an imbalance between reactive
oxygen species (ROS) generation and body's capability to detoxify the reactive mediators or
to fix the relating damage. ROS can regulate miRNA transcription, maturation, and function.
ROS directly modulate the activity of vital proteins that control posttranscriptional events in
the biogenesis of miRNAs (Di George critical region-8 protein; Dicer). A certain group of
transcription factors involved in the regulation of miRNA expression is upregulated under
oxidative stress and directly activates the transcription of a subset of miRNAs. ROS have
been directly implicated in epigenetic alternations such as DNA methylation and histone
modifications that control specific microRNA transcription (1). On the other hand, miRNAs
may in turn modulate the redox signalling pathways, altering their integrity, stability, and
functionality, thus contributing to the pathogenesis of multiple diseases: cancer,
neurodegenerative diseases, diabetes mellitus (2), ROS-related cardiac diseases, including
myocardial infarction, ischemia/reperfusion injury, cardiac hypertrophy and heart failure,
and are also considered as potential therapeutic targets and novel diagnostic tools., MikroRNK (miRNK) predstavljaju male, nekodirajuće RNK, dužine 22-24 nukleotida,
koje regulišu ekspresiju gena na post-transkripcionom nivou. Interakcija miRNK sa ciljnim
informacionim RNK (iRNK) u većini slučajeva dovodi do supresije ekspresije gena,
degradacijom ciljne iRNK ili inhibicijom translacije. Ove interakcije se dešavaju na
nekodirajućim 3’krajevima iRNK, ali mogu da se dese i na 5’ kraju ili čak na kodirajućem
regionu ciljne iRNK. Smatra se da na ovaj način, u humanom genomu, miRNK kontrolišu oko
30-60% gena koji kodiraju proteine. Oksidativni stres je stanje u kome postoji neravnoteža
između stvaranja reaktivnih vrsta kiseonika (slobodni radikali, ROS) i njihovog neutralisanja
od strane antioksidativne zaštite organizma. Pokazano je da ROS mogu da utiču na procese
transkripcije i sazrevanja miRNK kao i na njihovu funkciju. ROS direktno modulišu aktivnost
glavnih proteina koji učestvuju u post-transkripcionoj obradi u procesu biogeneze miRNK
(Di George critical region-8 protein i Dicer). Pod uticajem oksidativnog stresa može se
aktivirati transkripcija određenih familija miRNK, dejstvom na transkripcione faktore koji
učetvuju u tom procesu. Takođe, ROS utiču na epigenetske mehanizme regulacije ekspresije
miRNK, kao što su DNK metilacija i modifikacija histona (1). Sa druge strane, miRNK mogu da
utiču na aktivnost redoks signalnih puteva, menjajući njihovo funkcionisanje. Na taj način
miRNK doprinose patogenezi mnogih bolesti kao što su: različite vrste kancera,
neurodegenerativne bolesti, dijabetes melitus (2), bolesti srca, uključujući infarkt miokarda,
povredu nastalu ishemijom/reperfuzijom, srčanu hipertrofiju i srčanu insuficijenciju.
Takođe, miRNK se razmatraju kao potencijalni dijagnostički markeri i novi terapijski ciljevi.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "The role of microRNAs in oxidative stress regulation, Uloga mikroRNK u regulaciji oksidativnog stresa",
volume = "72",
number = "4 suplement",
pages = "S152-S153",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4482"
}

Munjas, J., Sopić, M., Ninić, A., Dobričić, M.,& Ležajić, V.. (2022). The role of microRNAs in oxidative stress regulation. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S152-S153.
https://hdl.handle.net/21.15107/rcub_farfar_4482

Munjas J, Sopić M, Ninić A, Dobričić M, Ležajić V. The role of microRNAs in oxidative stress regulation. in Arhiv za farmaciju. 2022;72(4 suplement):S152-S153.
https://hdl.handle.net/21.15107/rcub_farfar_4482 .

Munjas, Jelena, Sopić, Miron, Ninić, Ana, Dobričić, Marija, Ležajić, Višnja, "The role of microRNAs in oxidative stress regulation" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S152-S153,
https://hdl.handle.net/21.15107/rcub_farfar_4482 .

TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Stefanović, Aleksandra
AU  - Košir, Rok
AU  - Ninić, Ana
AU  - Joksić, Ivana
AU  - Antonić, Tamara
AU  - Spasojević-Kalimanovska, Vesna
AU  - Prosenc Zmrzljak, Uršula
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3979
AB  - Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Defects in trophoblast invasion, differentiation of extravillous trophoblasts and spiral artery remodeling are key factors in PE development. Currently there are no predictive biomarkers clinically available for PE. Recent technological advancements empowered transcriptome exploration and led to the discovery of numerous non-coding RNA species of which microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. They are implicated in the regulation of numerous cellular functions, and as such are being extensively explored as potential biomarkers for various diseases. Altered expression of numerous lncRNAs and miRNAs in placenta has been related to pathophysiological processes that occur in preeclampsia. In the following text we offer summary of the latest knowledge of the molecular mechanism by which lnRNAs and miRNAs (focusing on the chromosome 19 miRNA cluster (C19MC)) contribute to pathophysiology of PE development and their potential utility as biomarkers of PE, with special focus on sample selection and techniques for the quantification of lncRNAs and miRNAs in maternal circulation.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential
VL  - 22
IS  - 19
DO  - 10.3390/ijms221910652
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Stefanović, Aleksandra and Košir, Rok and Ninić, Ana and Joksić, Ivana and Antonić, Tamara and Spasojević-Kalimanovska, Vesna and Prosenc Zmrzljak, Uršula",
year = "2021",
abstract = "Preeclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Defects in trophoblast invasion, differentiation of extravillous trophoblasts and spiral artery remodeling are key factors in PE development. Currently there are no predictive biomarkers clinically available for PE. Recent technological advancements empowered transcriptome exploration and led to the discovery of numerous non-coding RNA species of which microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. They are implicated in the regulation of numerous cellular functions, and as such are being extensively explored as potential biomarkers for various diseases. Altered expression of numerous lncRNAs and miRNAs in placenta has been related to pathophysiological processes that occur in preeclampsia. In the following text we offer summary of the latest knowledge of the molecular mechanism by which lnRNAs and miRNAs (focusing on the chromosome 19 miRNA cluster (C19MC)) contribute to pathophysiology of PE development and their potential utility as biomarkers of PE, with special focus on sample selection and techniques for the quantification of lncRNAs and miRNAs in maternal circulation.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential",
volume = "22",
number = "19",
doi = "10.3390/ijms221910652"
}

Munjas, J., Sopić, M., Stefanović, A., Košir, R., Ninić, A., Joksić, I., Antonić, T., Spasojević-Kalimanovska, V.,& Prosenc Zmrzljak, U.. (2021). Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential. in International Journal of Molecular Sciences
MDPI., 22(19).
https://doi.org/10.3390/ijms221910652

Munjas J, Sopić M, Stefanović A, Košir R, Ninić A, Joksić I, Antonić T, Spasojević-Kalimanovska V, Prosenc Zmrzljak U. Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential. in International Journal of Molecular Sciences. 2021;22(19).
doi:10.3390/ijms221910652 .

Munjas, Jelena, Sopić, Miron, Stefanović, Aleksandra, Košir, Rok, Ninić, Ana, Joksić, Ivana, Antonić, Tamara, Spasojević-Kalimanovska, Vesna, Prosenc Zmrzljak, Uršula, "Non-coding RNAs in preeclampsia—molecular mechanisms and diagnostic potential" in International Journal of Molecular Sciences, 22, no. 19 (2021),
https://doi.org/10.3390/ijms221910652 . .

TY  - JOUR
AU  - Ninić, Ana
AU  - Bojanin, Dragana
AU  - Sopić, Miron
AU  - Mihajlović, Marija
AU  - Munjas, Jelena
AU  - Milenković, Tatjana
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3799
AB  - Objective: Type 1 diabetes (T1D) mellitus is one of the most frequent autoimmune diseases in childhood. Chronic complications are the main causes of cardiovascular morbidity and mortality in T1D. Although interactions between advanced glycation end products (AGE) and their receptors (RAGE) and transforming growth factor-β1 (TGF-β1) are implicated in development and progression of diabetic micro-and macro-vascular complications, they also have important roles in immune system regulation. Methods: Blood samples were obtained from 156 adolescents with T1D and 80 apparently healthy controls. T1D patients diagnosed with any other autoimmune disease and receiving any kind of drugs except insulin therapy were excluded from this study. Exclusion criteria for controls were positive family history of T1D and drugs/supplements application. TGF-β1 and transmembrane full-length RAGE (flRAGE) messenger ribonucleic acid (mRNA) levels in peripheral blood mononuclear cells (PBMC) were obtained by quantitative polymerase chain reaction (qPCR) method. Circulating levels of biochemical markers, TGF-β1 and soluble RAGE (sRAGE) levels were also determined. Results: TGF-β1 and flRAGE mRNA levels were significantly higher in controls compared to patients (p<0.001, for both). However, TGF-β1 and sRAGE levels were higher in patients than controls (p<0.001, for both). There were significant independent associations of all mRNA and protein levels with T1D. TGF-β1 mRNA was the only marker independently negatively associated with urinary albumin excretion rate in T1D adolescents (p=0.005). Conclusion: Our results indicated gene expression downregulation of TGF-β1 and flRAGE in PBMC of T1D adolescents. TGF-β1 mRNA downregulation may be useful for predicting early elevation of urinary albumin excretion rate.
PB  - Galenos
T2  - JCRPE Journal of Clinical Research in Pediatric Endocrinology
T1  - Transforming growth factor-β1 and receptor for advanced glycation end products gene expression and protein levels in adolescents with type 1 diabetes mellitus
VL  - 13
IS  - 1
SP  - 61
EP  - 71
DO  - 10.4274/jcrpe.galenos.2020.2020.0155
ER  - 

@article{
author = "Ninić, Ana and Bojanin, Dragana and Sopić, Miron and Mihajlović, Marija and Munjas, Jelena and Milenković, Tatjana and Stefanović, Aleksandra and Vekić, Jelena and Spasojević-Kalimanovska, Vesna",
year = "2021",
abstract = "Objective: Type 1 diabetes (T1D) mellitus is one of the most frequent autoimmune diseases in childhood. Chronic complications are the main causes of cardiovascular morbidity and mortality in T1D. Although interactions between advanced glycation end products (AGE) and their receptors (RAGE) and transforming growth factor-β1 (TGF-β1) are implicated in development and progression of diabetic micro-and macro-vascular complications, they also have important roles in immune system regulation. Methods: Blood samples were obtained from 156 adolescents with T1D and 80 apparently healthy controls. T1D patients diagnosed with any other autoimmune disease and receiving any kind of drugs except insulin therapy were excluded from this study. Exclusion criteria for controls were positive family history of T1D and drugs/supplements application. TGF-β1 and transmembrane full-length RAGE (flRAGE) messenger ribonucleic acid (mRNA) levels in peripheral blood mononuclear cells (PBMC) were obtained by quantitative polymerase chain reaction (qPCR) method. Circulating levels of biochemical markers, TGF-β1 and soluble RAGE (sRAGE) levels were also determined. Results: TGF-β1 and flRAGE mRNA levels were significantly higher in controls compared to patients (p<0.001, for both). However, TGF-β1 and sRAGE levels were higher in patients than controls (p<0.001, for both). There were significant independent associations of all mRNA and protein levels with T1D. TGF-β1 mRNA was the only marker independently negatively associated with urinary albumin excretion rate in T1D adolescents (p=0.005). Conclusion: Our results indicated gene expression downregulation of TGF-β1 and flRAGE in PBMC of T1D adolescents. TGF-β1 mRNA downregulation may be useful for predicting early elevation of urinary albumin excretion rate.",
publisher = "Galenos",
journal = "JCRPE Journal of Clinical Research in Pediatric Endocrinology",
title = "Transforming growth factor-β1 and receptor for advanced glycation end products gene expression and protein levels in adolescents with type 1 diabetes mellitus",
volume = "13",
number = "1",
pages = "61-71",
doi = "10.4274/jcrpe.galenos.2020.2020.0155"
}

Ninić, A., Bojanin, D., Sopić, M., Mihajlović, M., Munjas, J., Milenković, T., Stefanović, A., Vekić, J.,& Spasojević-Kalimanovska, V.. (2021). Transforming growth factor-β1 and receptor for advanced glycation end products gene expression and protein levels in adolescents with type 1 diabetes mellitus. in JCRPE Journal of Clinical Research in Pediatric Endocrinology
Galenos., 13(1), 61-71.
https://doi.org/10.4274/jcrpe.galenos.2020.2020.0155

Ninić A, Bojanin D, Sopić M, Mihajlović M, Munjas J, Milenković T, Stefanović A, Vekić J, Spasojević-Kalimanovska V. Transforming growth factor-β1 and receptor for advanced glycation end products gene expression and protein levels in adolescents with type 1 diabetes mellitus. in JCRPE Journal of Clinical Research in Pediatric Endocrinology. 2021;13(1):61-71.
doi:10.4274/jcrpe.galenos.2020.2020.0155 .

Ninić, Ana, Bojanin, Dragana, Sopić, Miron, Mihajlović, Marija, Munjas, Jelena, Milenković, Tatjana, Stefanović, Aleksandra, Vekić, Jelena, Spasojević-Kalimanovska, Vesna, "Transforming growth factor-β1 and receptor for advanced glycation end products gene expression and protein levels in adolescents with type 1 diabetes mellitus" in JCRPE Journal of Clinical Research in Pediatric Endocrinology, 13, no. 1 (2021):61-71,
https://doi.org/10.4274/jcrpe.galenos.2020.2020.0155 . .

TY  - CONF
AU  - Sopić, Miron
AU  - Šupljeglav, Branislava
AU  - Milojević, Ana
AU  - Mihajlović, Marija
AU  - Ninić, Ana
AU  - Munjas, Jelena
AU  - Gardijan, Vera
AU  - Radosavljević, Vojislav
AU  - Memon, Lidija
AU  - Zdravković, Marija
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5586
AB  - Background and Aims: Obstructive sleep apnea (OSA) is associated with increased risk of cardiovascular disease. Resistin is recognized as a potent proinflammatory cytokine that is able to influence atherosclerotic plaque progression through several mechanisms. ...
PB  - Elsevier
C3  - Atherosclerosis
T1  - Increased gene expression of resistin and CD36 in peripheral blood mononuclear cells is associated with hypercholesterolemia in patients with obstructive sleep apnea
VL  - 315
SP  - e48
EP  - e49
DO  - 10.1016/j.atherosclerosis.2020.10.150
ER  - 

@conference{
author = "Sopić, Miron and Šupljeglav, Branislava and Milojević, Ana and Mihajlović, Marija and Ninić, Ana and Munjas, Jelena and Gardijan, Vera and Radosavljević, Vojislav and Memon, Lidija and Zdravković, Marija and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Background and Aims: Obstructive sleep apnea (OSA) is associated with increased risk of cardiovascular disease. Resistin is recognized as a potent proinflammatory cytokine that is able to influence atherosclerotic plaque progression through several mechanisms. ...",
publisher = "Elsevier",
journal = "Atherosclerosis",
title = "Increased gene expression of resistin and CD36 in peripheral blood mononuclear cells is associated with hypercholesterolemia in patients with obstructive sleep apnea",
volume = "315",
pages = "e48-e49",
doi = "10.1016/j.atherosclerosis.2020.10.150"
}

Sopić, M., Šupljeglav, B., Milojević, A., Mihajlović, M., Ninić, A., Munjas, J., Gardijan, V., Radosavljević, V., Memon, L., Zdravković, M.,& Spasojević-Kalimanovska, V.. (2020). Increased gene expression of resistin and CD36 in peripheral blood mononuclear cells is associated with hypercholesterolemia in patients with obstructive sleep apnea. in Atherosclerosis
Elsevier., 315, e48-e49.
https://doi.org/10.1016/j.atherosclerosis.2020.10.150

Sopić M, Šupljeglav B, Milojević A, Mihajlović M, Ninić A, Munjas J, Gardijan V, Radosavljević V, Memon L, Zdravković M, Spasojević-Kalimanovska V. Increased gene expression of resistin and CD36 in peripheral blood mononuclear cells is associated with hypercholesterolemia in patients with obstructive sleep apnea. in Atherosclerosis. 2020;315:e48-e49.
doi:10.1016/j.atherosclerosis.2020.10.150 .

Sopić, Miron, Šupljeglav, Branislava, Milojević, Ana, Mihajlović, Marija, Ninić, Ana, Munjas, Jelena, Gardijan, Vera, Radosavljević, Vojislav, Memon, Lidija, Zdravković, Marija, Spasojević-Kalimanovska, Vesna, "Increased gene expression of resistin and CD36 in peripheral blood mononuclear cells is associated with hypercholesterolemia in patients with obstructive sleep apnea" in Atherosclerosis, 315 (2020):e48-e49,
https://doi.org/10.1016/j.atherosclerosis.2020.10.150 . .

TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Joksić, Ivana
AU  - Prosenc Zmrzljak, Ursula
AU  - Karadžov-Orlić, Nataša
AU  - Košir, Rok
AU  - Egić, Amira
AU  - Miković, Željko
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3669
PB  - Elsevier
T2  - Clinical Biochemistry
T1  - Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]
VL  - 85
SP  - 57
EP  - 57
DO  - 10.1016/j.clinbiochem.2020.08.011
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Joksić, Ivana and Prosenc Zmrzljak, Ursula and Karadžov-Orlić, Nataša and Košir, Rok and Egić, Amira and Miković, Željko and Ninić, Ana and Spasojević-Kalimanovska, Vesna",
year = "2020",
publisher = "Elsevier",
journal = "Clinical Biochemistry",
title = "Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]",
volume = "85",
pages = "57-57",
doi = "10.1016/j.clinbiochem.2020.08.011"
}

Munjas, J., Sopić, M., Joksić, I., Prosenc Zmrzljak, U., Karadžov-Orlić, N., Košir, R., Egić, A., Miković, Ž., Ninić, A.,& Spasojević-Kalimanovska, V.. (2020). Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]. in Clinical Biochemistry
Elsevier., 85, 57-57.
https://doi.org/10.1016/j.clinbiochem.2020.08.011

Munjas J, Sopić M, Joksić I, Prosenc Zmrzljak U, Karadžov-Orlić N, Košir R, Egić A, Miković Ž, Ninić A, Spasojević-Kalimanovska V. Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]. in Clinical Biochemistry. 2020;85:57-57.
doi:10.1016/j.clinbiochem.2020.08.011 .

Munjas, Jelena, Sopić, Miron, Joksić, Ivana, Prosenc Zmrzljak, Ursula, Karadžov-Orlić, Nataša, Košir, Rok, Egić, Amira, Miković, Željko, Ninić, Ana, Spasojević-Kalimanovska, Vesna, "Corrigendum to “Placenta-specific plasma miR518b is a potential biomarker for preeclampsia” [Clin. Biochem. 79 (2020) 28–33]" in Clinical Biochemistry, 85 (2020):57-57,
https://doi.org/10.1016/j.clinbiochem.2020.08.011 . .

TY  - JOUR
AU  - Joksić, Ivana
AU  - Miković, Željko
AU  - Filimonović, Dejan
AU  - Munjas, Jelena
AU  - Karadžov-Orlić, Nataša
AU  - Egić, Amira
AU  - Joksić, Gordana
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3618
AB  - Background:Recurrent pregnancy loss (RPL) is a heterogeneous condition affecting up to 5% of women of reproductive age. Inherited thrombophilia have been postulated as one  of  the  causes  of  RPL.  Here  we  examined  the  prevalence  of  nine  thrombophilic  gene  polymorphisms  among women  with  history  of  recurrent  miscarriages  and  fertile controls.Methods:The study included 70 women with history of at least  three  early  pregnancy  losses  and  31  fertile  controls with  no  miscarriages.  We  investigated  mutations  in  genes responsible  for  clotting  and  fibrinolysis,  including  factor  V(FV) Leiden, FV H1299R, factor II (FII) G20210A, methyl-ene  tetrahydrofolate  reductase  (MTHFR)  C677T  and A1298C,  factor  XIII  (FXIII)  V34L,  plasminogen  activator inhibitor-1 (PAI-1) 4G/5G and endothelial protein C receptor  (EPCR)  H1  and  H3  haplotypes  using  reverse  polymerase  chain  reaction  ViennaLab  cardiovascular  disease StrippAssays. Results:Our  results  showed  no  significant  increase  inprevalence  of  tested  polymorphisms  in  women  with  RPL. However, relative risk for PRL among women heterozygousfor FXIII V34L was 2.81 times increased (OR 2.81, 95% CI1.15–6.87,  P=0.023).  Haplotype  analysis  showed  that combined  presence  of  high-risk  genotypes  for  FXIII  andPAI-1  significantly  increases  risk  for  RPL  (OR  13.98,  CI95% 1.11–17.46, P=0.044).Conclusions:This  is  the  first  study  in  Serbian  population that investigated prevalence of FVR2, A1298C, FXIII V34Land  EPCR  gene  variants.  Compound  heterozygosity  forFXIII V34L and PAI-1 4G is significant risk factor for recur-rent miscarriage. Our results should be viewed in context of small case-control study, so further large prospective studies are need for confirmation of our findings.
AB  - Uvod: Ponavljani spontani pobačaji (PSP) su etiološki heterogeni i javljaju se kod 5% parova u reproduktivnom period. Jedan od mogućih uzroka PSP su i nasledne trombofilije. U okviru ove studije analizirali smo učestalost devet trombofilnih polimorfizama kod pacijentkinja sa ponavljanim spontanim pobačajima. Metode: Ispitanici su u studiji podeljeni u dve grupe na osnovu anamnestičkih podataka o broju spontanih pobačaja (70 u grupi sa PSP i 31 u kontrolnoj grupi). Ispitivani su sledeći genski polimorfizmi: faktor V Lajden (FVL), FVR2, faktor II (FII) G21210A, metilentetrahidrofolat reduktaza (MTHFR) C677T i A1298C polimorfizmi, inhibitor aktivatora plazminogena 1 (PAI-1) 4G/5G, faktor XIII (FXIII) V34L i endotelni protein C receptor (EPRC) H1, H2 i H3 haplotipovi. Za detekciju navedenih polimorfizama je korišćena metoda multipleks reakcije lančanog umnožavanja i reverzne hibridizacije na ViennaLab stripovima. Rezultati: Dobijeni rezultati nisu pokazali povećanu učestalost ispitivanih polimorfizama u grupi sa PSP. Posmatrajući uticaj pojedinačnih polimorfizama na ishod trudnoće pokazano je da polimorfizam FXIII V34L povećava rizik za ponavljane spontane pobačaje (OR 2,81, 95%CI 1,15-6,87, P=0,023). Analizom haplotipova ustanovljeno je da kombinovano prisustvo V34L i PAI-1 4G varijanti značajno povećava rizik za PSP (OR 13,98, CI 95% 1,11-17,46, P=0,044). Zaključak: Ovo je prva studija koja je ispitivala prevalencu FVR2, A1298C, FXIII V34L and EPCR polimorfizama u populaciji žena iz Srbije. Složeni heterozigoti za FXIII V34L i PAI-1 4G polimorfizme imaju značajno povišen rizik sa ponavljane gubitke trudnoće. Radi potvrde dobijenih rezultata potrebne su veće prospektivne studije.
PB  - Beograd : Društvo medicinskih biohemičara Srbije
T2  - Journal of Medical Biochemistry
T1  - Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population
T1  - Kombinovano prisustvo genskih polimorfizma faktora koagulacije XIII V34L i inhibitora plazminogen aktivatora 1 4G/5G značajno utiče na rizik od spontanog pobačaja u srpskoj populaciji
VL  - 39
IS  - 2
SP  - 199
EP  - 207
DO  - 10.2478/jomb-2019-0028
ER  - 

@article{
author = "Joksić, Ivana and Miković, Željko and Filimonović, Dejan and Munjas, Jelena and Karadžov-Orlić, Nataša and Egić, Amira and Joksić, Gordana",
year = "2020",
abstract = "Background:Recurrent pregnancy loss (RPL) is a heterogeneous condition affecting up to 5% of women of reproductive age. Inherited thrombophilia have been postulated as one  of  the  causes  of  RPL.  Here  we  examined  the  prevalence  of  nine  thrombophilic  gene  polymorphisms  among women  with  history  of  recurrent  miscarriages  and  fertile controls.Methods:The study included 70 women with history of at least  three  early  pregnancy  losses  and  31  fertile  controls with  no  miscarriages.  We  investigated  mutations  in  genes responsible  for  clotting  and  fibrinolysis,  including  factor  V(FV) Leiden, FV H1299R, factor II (FII) G20210A, methyl-ene  tetrahydrofolate  reductase  (MTHFR)  C677T  and A1298C,  factor  XIII  (FXIII)  V34L,  plasminogen  activator inhibitor-1 (PAI-1) 4G/5G and endothelial protein C receptor  (EPCR)  H1  and  H3  haplotypes  using  reverse  polymerase  chain  reaction  ViennaLab  cardiovascular  disease StrippAssays. Results:Our  results  showed  no  significant  increase  inprevalence  of  tested  polymorphisms  in  women  with  RPL. However, relative risk for PRL among women heterozygousfor FXIII V34L was 2.81 times increased (OR 2.81, 95% CI1.15–6.87,  P=0.023).  Haplotype  analysis  showed  that combined  presence  of  high-risk  genotypes  for  FXIII  andPAI-1  significantly  increases  risk  for  RPL  (OR  13.98,  CI95% 1.11–17.46, P=0.044).Conclusions:This  is  the  first  study  in  Serbian  population that investigated prevalence of FVR2, A1298C, FXIII V34Land  EPCR  gene  variants.  Compound  heterozygosity  forFXIII V34L and PAI-1 4G is significant risk factor for recur-rent miscarriage. Our results should be viewed in context of small case-control study, so further large prospective studies are need for confirmation of our findings., Uvod: Ponavljani spontani pobačaji (PSP) su etiološki heterogeni i javljaju se kod 5% parova u reproduktivnom period. Jedan od mogućih uzroka PSP su i nasledne trombofilije. U okviru ove studije analizirali smo učestalost devet trombofilnih polimorfizama kod pacijentkinja sa ponavljanim spontanim pobačajima. Metode: Ispitanici su u studiji podeljeni u dve grupe na osnovu anamnestičkih podataka o broju spontanih pobačaja (70 u grupi sa PSP i 31 u kontrolnoj grupi). Ispitivani su sledeći genski polimorfizmi: faktor V Lajden (FVL), FVR2, faktor II (FII) G21210A, metilentetrahidrofolat reduktaza (MTHFR) C677T i A1298C polimorfizmi, inhibitor aktivatora plazminogena 1 (PAI-1) 4G/5G, faktor XIII (FXIII) V34L i endotelni protein C receptor (EPRC) H1, H2 i H3 haplotipovi. Za detekciju navedenih polimorfizama je korišćena metoda multipleks reakcije lančanog umnožavanja i reverzne hibridizacije na ViennaLab stripovima. Rezultati: Dobijeni rezultati nisu pokazali povećanu učestalost ispitivanih polimorfizama u grupi sa PSP. Posmatrajući uticaj pojedinačnih polimorfizama na ishod trudnoće pokazano je da polimorfizam FXIII V34L povećava rizik za ponavljane spontane pobačaje (OR 2,81, 95%CI 1,15-6,87, P=0,023). Analizom haplotipova ustanovljeno je da kombinovano prisustvo V34L i PAI-1 4G varijanti značajno povećava rizik za PSP (OR 13,98, CI 95% 1,11-17,46, P=0,044). Zaključak: Ovo je prva studija koja je ispitivala prevalencu FVR2, A1298C, FXIII V34L and EPCR polimorfizama u populaciji žena iz Srbije. Složeni heterozigoti za FXIII V34L i PAI-1 4G polimorfizme imaju značajno povišen rizik sa ponavljane gubitke trudnoće. Radi potvrde dobijenih rezultata potrebne su veće prospektivne studije.",
publisher = "Beograd : Društvo medicinskih biohemičara Srbije",
journal = "Journal of Medical Biochemistry",
title = "Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population, Kombinovano prisustvo genskih polimorfizma faktora koagulacije XIII V34L i inhibitora plazminogen aktivatora 1 4G/5G značajno utiče na rizik od spontanog pobačaja u srpskoj populaciji",
volume = "39",
number = "2",
pages = "199-207",
doi = "10.2478/jomb-2019-0028"
}

Joksić, I., Miković, Ž., Filimonović, D., Munjas, J., Karadžov-Orlić, N., Egić, A.,& Joksić, G.. (2020). Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population. in Journal of Medical Biochemistry
Beograd : Društvo medicinskih biohemičara Srbije., 39(2), 199-207.
https://doi.org/10.2478/jomb-2019-0028

Joksić I, Miković Ž, Filimonović D, Munjas J, Karadžov-Orlić N, Egić A, Joksić G. Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population. in Journal of Medical Biochemistry. 2020;39(2):199-207.
doi:10.2478/jomb-2019-0028 .

Joksić, Ivana, Miković, Željko, Filimonović, Dejan, Munjas, Jelena, Karadžov-Orlić, Nataša, Egić, Amira, Joksić, Gordana, "Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in serbian population" in Journal of Medical Biochemistry, 39, no. 2 (2020):199-207,
https://doi.org/10.2478/jomb-2019-0028 . .

TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Joksić, Ivana
AU  - Prosenc Zmrzljak, Ursula
AU  - Karadžov-Orlić, Nataša
AU  - Košir, Rok
AU  - Egić, Amira
AU  - Miković, Željko
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3602
AB  - Introduction: MicroRNAs have a significant role in the pathogenesis of preeclampsia. Circulating microRNAs could represent a potential biomarker for preeclampsia. The aim of this study was to evaluate plasma miR210-3p and miR518b in preeclampsia and healthy pregnancy for the first time by digital droplet PCR (ddPCR). Methods: Thirty-six pregnant women (seventeen healthy pregnancies, nineteen preeclampsia patients) were involved from the Clinic for Gynaecology and Obstetrics “Narodni front” in Belgrade, Serbia. Plasma miR210-3p, miR518b and cel-miR-39 as a spike-in control were measured by ddPCR. Results: MiR518b was significantly elevated in preeclampsia compared to a healthy pregnancy (P = 0.034; 0.302(0.217–0.421) vs. 0.171(0.110–0.266)). MiR210-3p showed no significant difference between the two groups (P = 0.951). The adjustment of miR518b was made for a gestational age and smoking status and the difference between the preeclampsia and healthy pregnancy group was more significant (P = 0.026; 0.300(0.216–0.419) vs. 0.172(0.121–0.245)). Plasma miR-518b was significantly higher in the group of preeclampsia patients with proteinuria above the 75th percentile for the group (P=0.033), in women who smoked (P=0.039), and was positively related to uric acid in preeclampsia (P = 0.018, r = 0.536). Plasma miR518b was able to significantly discriminate between preeclampsia and healthy pregnancy, yielding AUC of 0.712 (95%CI:0.539–0.891), P = 0.028. Conclusions: In this study plasma microRNA were measured for the first time in preeclampsia and healthy pregnancies with ddPCR. Placenta-specific miR-518b could serve as a potential biomarker for discriminating preeclampsia and healthy pregnancy, which should be confirmed on a larger study population. This study has failed to confirm the same potential for miR210-3p.
PB  - Elsevier
T2  - Clinical Biochemistry
T1  - Placenta-specific plasma miR518b is a potential biomarker for preeclampsia
VL  - 79
SP  - 28
EP  - 33
DO  - 10.1016/j.clinbiochem.2020.02.012
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Joksić, Ivana and Prosenc Zmrzljak, Ursula and Karadžov-Orlić, Nataša and Košir, Rok and Egić, Amira and Miković, Željko and Ninić, Ana and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "Introduction: MicroRNAs have a significant role in the pathogenesis of preeclampsia. Circulating microRNAs could represent a potential biomarker for preeclampsia. The aim of this study was to evaluate plasma miR210-3p and miR518b in preeclampsia and healthy pregnancy for the first time by digital droplet PCR (ddPCR). Methods: Thirty-six pregnant women (seventeen healthy pregnancies, nineteen preeclampsia patients) were involved from the Clinic for Gynaecology and Obstetrics “Narodni front” in Belgrade, Serbia. Plasma miR210-3p, miR518b and cel-miR-39 as a spike-in control were measured by ddPCR. Results: MiR518b was significantly elevated in preeclampsia compared to a healthy pregnancy (P = 0.034; 0.302(0.217–0.421) vs. 0.171(0.110–0.266)). MiR210-3p showed no significant difference between the two groups (P = 0.951). The adjustment of miR518b was made for a gestational age and smoking status and the difference between the preeclampsia and healthy pregnancy group was more significant (P = 0.026; 0.300(0.216–0.419) vs. 0.172(0.121–0.245)). Plasma miR-518b was significantly higher in the group of preeclampsia patients with proteinuria above the 75th percentile for the group (P=0.033), in women who smoked (P=0.039), and was positively related to uric acid in preeclampsia (P = 0.018, r = 0.536). Plasma miR518b was able to significantly discriminate between preeclampsia and healthy pregnancy, yielding AUC of 0.712 (95%CI:0.539–0.891), P = 0.028. Conclusions: In this study plasma microRNA were measured for the first time in preeclampsia and healthy pregnancies with ddPCR. Placenta-specific miR-518b could serve as a potential biomarker for discriminating preeclampsia and healthy pregnancy, which should be confirmed on a larger study population. This study has failed to confirm the same potential for miR210-3p.",
publisher = "Elsevier",
journal = "Clinical Biochemistry",
title = "Placenta-specific plasma miR518b is a potential biomarker for preeclampsia",
volume = "79",
pages = "28-33",
doi = "10.1016/j.clinbiochem.2020.02.012"
}

Munjas, J., Sopić, M., Joksić, I., Prosenc Zmrzljak, U., Karadžov-Orlić, N., Košir, R., Egić, A., Miković, Ž., Ninić, A.,& Spasojević-Kalimanovska, V.. (2020). Placenta-specific plasma miR518b is a potential biomarker for preeclampsia. in Clinical Biochemistry
Elsevier., 79, 28-33.
https://doi.org/10.1016/j.clinbiochem.2020.02.012

Munjas J, Sopić M, Joksić I, Prosenc Zmrzljak U, Karadžov-Orlić N, Košir R, Egić A, Miković Ž, Ninić A, Spasojević-Kalimanovska V. Placenta-specific plasma miR518b is a potential biomarker for preeclampsia. in Clinical Biochemistry. 2020;79:28-33.
doi:10.1016/j.clinbiochem.2020.02.012 .

Munjas, Jelena, Sopić, Miron, Joksić, Ivana, Prosenc Zmrzljak, Ursula, Karadžov-Orlić, Nataša, Košir, Rok, Egić, Amira, Miković, Željko, Ninić, Ana, Spasojević-Kalimanovska, Vesna, "Placenta-specific plasma miR518b is a potential biomarker for preeclampsia" in Clinical Biochemistry, 79 (2020):28-33,
https://doi.org/10.1016/j.clinbiochem.2020.02.012 . .

TY  - JOUR
AU  - Kotur-Stevuljević, Jelena
AU  - Vekić, Jelena
AU  - Stefanović, Aleksandra
AU  - Zeljković, Aleksandra
AU  - Ninić, Ana
AU  - Ivanišević, Jasmina
AU  - Miljković, Milica
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Mihajlović, Marija
AU  - Spasić, Slavica
AU  - Jelić-Ivanović, Zorana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3615
AB  - A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features. © 2019 International Union of Biochemistry and Molecular Biology
PB  - Blackwell Publishing Inc.
T2  - BioFactors
T1  - Paraoxonase 1 and atherosclerosis-related diseases
VL  - 46
IS  - 2
SP  - 193
EP  - 205
DO  - 10.1002/biof.1549
ER  - 

@article{
author = "Kotur-Stevuljević, Jelena and Vekić, Jelena and Stefanović, Aleksandra and Zeljković, Aleksandra and Ninić, Ana and Ivanišević, Jasmina and Miljković, Milica and Sopić, Miron and Munjas, Jelena and Mihajlović, Marija and Spasić, Slavica and Jelić-Ivanović, Zorana and Spasojević-Kalimanovska, Vesna",
year = "2020",
abstract = "A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features. © 2019 International Union of Biochemistry and Molecular Biology",
publisher = "Blackwell Publishing Inc.",
journal = "BioFactors",
title = "Paraoxonase 1 and atherosclerosis-related diseases",
volume = "46",
number = "2",
pages = "193-205",
doi = "10.1002/biof.1549"
}

Kotur-Stevuljević, J., Vekić, J., Stefanović, A., Zeljković, A., Ninić, A., Ivanišević, J., Miljković, M., Sopić, M., Munjas, J., Mihajlović, M., Spasić, S., Jelić-Ivanović, Z.,& Spasojević-Kalimanovska, V.. (2020). Paraoxonase 1 and atherosclerosis-related diseases. in BioFactors
Blackwell Publishing Inc.., 46(2), 193-205.
https://doi.org/10.1002/biof.1549

Kotur-Stevuljević J, Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, Miljković M, Sopić M, Munjas J, Mihajlović M, Spasić S, Jelić-Ivanović Z, Spasojević-Kalimanovska V. Paraoxonase 1 and atherosclerosis-related diseases. in BioFactors. 2020;46(2):193-205.
doi:10.1002/biof.1549 .

Kotur-Stevuljević, Jelena, Vekić, Jelena, Stefanović, Aleksandra, Zeljković, Aleksandra, Ninić, Ana, Ivanišević, Jasmina, Miljković, Milica, Sopić, Miron, Munjas, Jelena, Mihajlović, Marija, Spasić, Slavica, Jelić-Ivanović, Zorana, Spasojević-Kalimanovska, Vesna, "Paraoxonase 1 and atherosclerosis-related diseases" in BioFactors, 46, no. 2 (2020):193-205,
https://doi.org/10.1002/biof.1549 . .

TY  - JOUR
AU  - Ninić, Ana
AU  - Bogavac-Stanojević, Nataša
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Kotur-Stevuljević, Jelena
AU  - Miljković, Milica
AU  - Gojković, Tamara
AU  - Kalimanovska-Oštrić, Dimitra
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3339
AB  - Background: Coronary artery disease (CAD) is one of the most important causes of mortality and morbidity in wide world population. Dyslipidemia, inflammation and oxidative stress may contribute to disruption of endothelium structure and function, atherosclerosis and CAD. Our study was aimed to determine whether Cu/Zn superoxide dismutase (Cu/Zn SOD) and Mn superoxide dismutase (Mn SOD) gene expression could be modulated by oxidative stress in CAD patients. Methods: This study included 77 CAD patients and 31 apparently healthy persons. Serum lipid levels, high sensitivity C-reactive protein (hsCRP), total antioxidant status (TAS) and thiobarbituric acid-reacting substances (TBARS) were measured. SOD isoenzymes gene expression was determined in peripheral blood mononuclear cells using quantitative polymerase chain reaction. Results: Mn SOD messenger ribonucleic acid (mRNA) levels were significantly lower in CAD patients than in controls (p=0.011), while Cu/Zn SOD mRNA levels did not change significantly between tested groups (p=0.091). We found significantly lower high-density lipoprotein-cholesterol (HDL-c) (p lt 0.001) and TAS (p lt 0.001) levels and significantly higher hsCRP (p=0.002) and TBARS (p lt 0.001) in CAD patients than in controls. There were significant positive correlations between TAS and Mn SOD mRNA (rho=0.243, p=0.020) and TAS and Cu/Zn SOD mRNA (rho=0.359, p lt 0.001). TBARS negatively correlated only with Cu/Zn SOD mRNA (rho=-0.215, p=0.040). TAS levels remained independent predictor for Mn SOD mRNA levels (OR = 2.995, p=0.034). Conclusions: Results of this study showed that Mn SOD gene expression were decreased in CAD patients compared to controls and can be modulated by nonenzymatic antioxidant status in blood.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Superoxide dismutase isoenzymes gene expression in peripheral blood mononuclear cells in patients with coronary artery disease
VL  - 38
IS  - 3
SP  - 284
EP  - 291
DO  - 10.2478/jomb-2018-0041
ER  - 

@article{
author = "Ninić, Ana and Bogavac-Stanojević, Nataša and Sopić, Miron and Munjas, Jelena and Kotur-Stevuljević, Jelena and Miljković, Milica and Gojković, Tamara and Kalimanovska-Oštrić, Dimitra and Spasojević-Kalimanovska, Vesna",
year = "2019",
abstract = "Background: Coronary artery disease (CAD) is one of the most important causes of mortality and morbidity in wide world population. Dyslipidemia, inflammation and oxidative stress may contribute to disruption of endothelium structure and function, atherosclerosis and CAD. Our study was aimed to determine whether Cu/Zn superoxide dismutase (Cu/Zn SOD) and Mn superoxide dismutase (Mn SOD) gene expression could be modulated by oxidative stress in CAD patients. Methods: This study included 77 CAD patients and 31 apparently healthy persons. Serum lipid levels, high sensitivity C-reactive protein (hsCRP), total antioxidant status (TAS) and thiobarbituric acid-reacting substances (TBARS) were measured. SOD isoenzymes gene expression was determined in peripheral blood mononuclear cells using quantitative polymerase chain reaction. Results: Mn SOD messenger ribonucleic acid (mRNA) levels were significantly lower in CAD patients than in controls (p=0.011), while Cu/Zn SOD mRNA levels did not change significantly between tested groups (p=0.091). We found significantly lower high-density lipoprotein-cholesterol (HDL-c) (p lt 0.001) and TAS (p lt 0.001) levels and significantly higher hsCRP (p=0.002) and TBARS (p lt 0.001) in CAD patients than in controls. There were significant positive correlations between TAS and Mn SOD mRNA (rho=0.243, p=0.020) and TAS and Cu/Zn SOD mRNA (rho=0.359, p lt 0.001). TBARS negatively correlated only with Cu/Zn SOD mRNA (rho=-0.215, p=0.040). TAS levels remained independent predictor for Mn SOD mRNA levels (OR = 2.995, p=0.034). Conclusions: Results of this study showed that Mn SOD gene expression were decreased in CAD patients compared to controls and can be modulated by nonenzymatic antioxidant status in blood.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Superoxide dismutase isoenzymes gene expression in peripheral blood mononuclear cells in patients with coronary artery disease",
volume = "38",
number = "3",
pages = "284-291",
doi = "10.2478/jomb-2018-0041"
}

Ninić, A., Bogavac-Stanojević, N., Sopić, M., Munjas, J., Kotur-Stevuljević, J., Miljković, M., Gojković, T., Kalimanovska-Oštrić, D.,& Spasojević-Kalimanovska, V.. (2019). Superoxide dismutase isoenzymes gene expression in peripheral blood mononuclear cells in patients with coronary artery disease. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 284-291.
https://doi.org/10.2478/jomb-2018-0041

Ninić A, Bogavac-Stanojević N, Sopić M, Munjas J, Kotur-Stevuljević J, Miljković M, Gojković T, Kalimanovska-Oštrić D, Spasojević-Kalimanovska V. Superoxide dismutase isoenzymes gene expression in peripheral blood mononuclear cells in patients with coronary artery disease. in Journal of Medical Biochemistry. 2019;38(3):284-291.
doi:10.2478/jomb-2018-0041 .

Ninić, Ana, Bogavac-Stanojević, Nataša, Sopić, Miron, Munjas, Jelena, Kotur-Stevuljević, Jelena, Miljković, Milica, Gojković, Tamara, Kalimanovska-Oštrić, Dimitra, Spasojević-Kalimanovska, Vesna, "Superoxide dismutase isoenzymes gene expression in peripheral blood mononuclear cells in patients with coronary artery disease" in Journal of Medical Biochemistry, 38, no. 3 (2019):284-291,
https://doi.org/10.2478/jomb-2018-0041 . .

TY  - JOUR
AU  - Janać, Jelena
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Dimitrijević-Srećković, Vesna
AU  - Miljković, Milica
AU  - Stefanović, Aleksandra
AU  - Munjas, Jelena
AU  - Vekić, Jelena
AU  - Kotur-Stevuljević, Jelena
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3293
AB  - Background: Non-alcoholic fatty liver disease is a frequent ailment with known complications, including those within the cardiovascular system. Associations between several indicators of high-density lipoprotein metabolism and function with clinical and laboratory parameters for the assessment of fatty liver index, a surrogate marker of non-alcoholic fatty liver disease, were evaluated. Methods: The study comprised 130 patients classified according to fatty liver index values: fatty liver index  lt  30, fatty liver index 30–59 (the intermediate group) and fatty liver index ⩾ 60. Lecithin–cholesterol acyltransferase and cholesteryl ester transfer protein activities were determined. Paraoxonase 1 concentration and its activity, paraoxonase 3 concentration and high-density lipoprotein subclass distribution were assessed. Results: Increased lecithin–cholesterol acyltransferase activity correlated with increased fatty liver index (P  lt  0.001). Paraoxonase 3 concentration was lower in the fatty liver index ⩾ 60 group compared with the fatty liver index  lt  30 group (P  lt  0.05). Cholesteryl ester transfer protein activity, paraoxonase 1 concentration and its activity did not significantly differ across the fatty liver index groups. The relative proportion of small-sized high-density lipoprotein 3 subclass was higher in the fatty liver index ⩾ 60 group compared with the other two fatty liver index groups (P  lt  0.01). Lecithin–cholesterol acyltransferase activity positively associated with the fatty liver index ⩾ 60 group and remained significant after adjustment for other potential confounders. Only the triglyceride concentration remained significantly associated with lecithin–cholesterol acyltransferase activity when the parameters that constitute the fatty liver index equation were examined. Conclusions: Higher lecithin–cholesterol acyltransferase activity is associated with elevated fatty liver index values. Significant independent association between triglycerides and lecithin–cholesterol acyltransferase activity might indicate a role of hypertriglyceridaemia in alterations of lecithin–cholesterol acyltransferase activity in individuals with elevated fatty liver index.
PB  - Sage Publications Ltd
T2  - Annals of Clinical Biochemistry
T1  - The association between lecithin–cholesterol acyltransferase activity and fatty liver index
VL  - 56
IS  - 5
SP  - 583
EP  - 592
DO  - 10.1177/0004563219853596
ER  - 

@article{
author = "Janać, Jelena and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Dimitrijević-Srećković, Vesna and Miljković, Milica and Stefanović, Aleksandra and Munjas, Jelena and Vekić, Jelena and Kotur-Stevuljević, Jelena and Spasojević-Kalimanovska, Vesna",
year = "2019",
abstract = "Background: Non-alcoholic fatty liver disease is a frequent ailment with known complications, including those within the cardiovascular system. Associations between several indicators of high-density lipoprotein metabolism and function with clinical and laboratory parameters for the assessment of fatty liver index, a surrogate marker of non-alcoholic fatty liver disease, were evaluated. Methods: The study comprised 130 patients classified according to fatty liver index values: fatty liver index  lt  30, fatty liver index 30–59 (the intermediate group) and fatty liver index ⩾ 60. Lecithin–cholesterol acyltransferase and cholesteryl ester transfer protein activities were determined. Paraoxonase 1 concentration and its activity, paraoxonase 3 concentration and high-density lipoprotein subclass distribution were assessed. Results: Increased lecithin–cholesterol acyltransferase activity correlated with increased fatty liver index (P  lt  0.001). Paraoxonase 3 concentration was lower in the fatty liver index ⩾ 60 group compared with the fatty liver index  lt  30 group (P  lt  0.05). Cholesteryl ester transfer protein activity, paraoxonase 1 concentration and its activity did not significantly differ across the fatty liver index groups. The relative proportion of small-sized high-density lipoprotein 3 subclass was higher in the fatty liver index ⩾ 60 group compared with the other two fatty liver index groups (P  lt  0.01). Lecithin–cholesterol acyltransferase activity positively associated with the fatty liver index ⩾ 60 group and remained significant after adjustment for other potential confounders. Only the triglyceride concentration remained significantly associated with lecithin–cholesterol acyltransferase activity when the parameters that constitute the fatty liver index equation were examined. Conclusions: Higher lecithin–cholesterol acyltransferase activity is associated with elevated fatty liver index values. Significant independent association between triglycerides and lecithin–cholesterol acyltransferase activity might indicate a role of hypertriglyceridaemia in alterations of lecithin–cholesterol acyltransferase activity in individuals with elevated fatty liver index.",
publisher = "Sage Publications Ltd",
journal = "Annals of Clinical Biochemistry",
title = "The association between lecithin–cholesterol acyltransferase activity and fatty liver index",
volume = "56",
number = "5",
pages = "583-592",
doi = "10.1177/0004563219853596"
}

Janać, J., Zeljković, A., Jelić-Ivanović, Z., Dimitrijević-Srećković, V., Miljković, M., Stefanović, A., Munjas, J., Vekić, J., Kotur-Stevuljević, J.,& Spasojević-Kalimanovska, V.. (2019). The association between lecithin–cholesterol acyltransferase activity and fatty liver index. in Annals of Clinical Biochemistry
Sage Publications Ltd., 56(5), 583-592.
https://doi.org/10.1177/0004563219853596

Janać J, Zeljković A, Jelić-Ivanović Z, Dimitrijević-Srećković V, Miljković M, Stefanović A, Munjas J, Vekić J, Kotur-Stevuljević J, Spasojević-Kalimanovska V. The association between lecithin–cholesterol acyltransferase activity and fatty liver index. in Annals of Clinical Biochemistry. 2019;56(5):583-592.
doi:10.1177/0004563219853596 .

Janać, Jelena, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Dimitrijević-Srećković, Vesna, Miljković, Milica, Stefanović, Aleksandra, Munjas, Jelena, Vekić, Jelena, Kotur-Stevuljević, Jelena, Spasojević-Kalimanovska, Vesna, "The association between lecithin–cholesterol acyltransferase activity and fatty liver index" in Annals of Clinical Biochemistry, 56, no. 5 (2019):583-592,
https://doi.org/10.1177/0004563219853596 . .

TY  - THES
AU  - Munjas, Jelena
PY  - 2018
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=5843
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:17745/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=2048261986
UR  - http://nardus.mpn.gov.rs/123456789/9554
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3401
AB  - Ishemijska bolest srca (IBS) danas predstavlja jedan od glavnih uzroka smrtnostiu svetu. U osnovi ove bolesti se nalazi ateroskleroza koja predstavlja multifaktorsko,hronično inflamatorno oboljenje indukovano ćelijskim i imunološkim odgovoromvaskularnog zida na metaboličku povredu. Humani rezistin je proinflamatorni protein,koji može imati značajnu ulogu u razvoju ateroskleroze i IBS. Ipak, kliničke studijeizvedene do sada došle su do oprečnih zaključaka vezane za ulogu ovog proteina u IBS.Kako bi se doprinelo boljem razumevanju uloge rezistina u ishemijskoj bolestisrca, ciljevi ovog istraživanja su bili određivanje nivoa iRNK rezistina i njegovogreceptora CAP1 u mononuklearnim ćelijama periferne krvi i koncentracija rezistina ukrvi pacijenata sa IBS i zdravih ispitanika, koji su činili kontrolnu grupu (KG),ispitivanje njihove međusobne povezanosti, povezanosti sa genskom ekspresijom IL-6 iCD36 i povezanosti sa lipidnim i nelipidnim faktorima rizika za razvoj ateroskleroze.U ovu studiju uključeno je 95 pacijenata sa indikacijama za koronarnuangiografiju i 33 ZI. Nivoi iRNK ispitivanih parametara su određeni metodom qPCR-a,koncentracije rezistina ELISA metodom, a subklase lipoproteinskih česticaelektroforezom na gradijentu nedenaturišućeg poliakrilamidnog gela.Koncentracije rezistina, nivoi iRNK CAP1 i CD36 su bili značajno viši kod svihgrupa pacijenata sa IBS u odnosu na KG (p<0,001; p<0,001; p<0,001, redom). Pacijentisa akutnim koronarnim sindromom su imali značajno više koncentracije rezistina uodnosu na druge grupe pacijenata (pstabilna angina pektoris=0,028; pbez anginoznih tegoba i značajnestenoze=0,003). Nivoi iRNK rezistina se nisu značajno razlikovali između ispitivanihgrupa. Pacijenti sa sadržajem malih gustih LDL (mgLDL) čestica ≥50% su imaliznačajno više koncentracije rezistina (p=0,031) i nivoe iRNK rezistina (p=0,004) uodnosu na pacijente sa sadržajem mgLDL čestica <50%. Nezavisni prediktorikoncentracija rezistina su bili kreatinin i ukupni holesterol, adjR2=0,298; nivoa iRNKrezistina dijametar LDL čestica i nivoi iRNK CD36, adjR2=0,192; nivoa iRNK CAP1trigliceridi i nivoi iRNK CD36, adjR2=0,352; nivoa iRNK CD36 hsCRP, kreatinin inivoi iRNK CAP1, adjR2=0,505...
AB  - Ischemic heart disease (IHD) is one of the major causes of morbidity and loss ofquality of life across the globe. The pathogenesis of IHD lays in the development ofdyslipidemia, increased proinflammatory processes and consequently atherosclerosisevolvement and progression. Human resistin is a proinflammatory cytokine, with apotential role in atherosclerosis and IHD development. However, clinical studiesconducted so far have been inconsistent regarding resistin’s role in IHD.The aims of this study were to determine resistin mRNA levels and mRNAlevels of resistin receptor, CAP1, in peripheral blood mononuclear cells (PBMC) andcirculating resistin concentrations in IHD patients and healthy subjects (HS), to evaluatetheir interconnection and association with gene expression levels of IL-6 and CD36, aswell as their association with lipid and non-lipid atherosclerosis risk factors.This study included 95 patients requiring coronary angiography and 33 HS.Circulating resistin was measured by ELISA; PBMC resistin mRNA was determined byqPCR. LDL and HDL subclasses were determined by gradient gel electrophoresis.Plasma resistin, CAP1 and CD36 mRNA were significantly higher in all groupsof IHD patients compared to HS (P<0.001; P<0.001; P<0.001, respectively). Acutecoronary syndrome patients had significantly higher plasma resistin compared to othergroups of patients (P=0.028; P=0.003). Resistin mRNA levels were not significantlydifferent between any of the investigated groups. Plasma resistin (P=0.031) and resistinmRNA (P=0.004) were significantly higher in patients with the proportion of sdLDLparticles ≥50%, compared to the group with the relative proportion of sdLDL particles<50%. Multiple linear regression analysis identified creatinine and total cholesterol asindependent predictors of plasma resistin (adjR2=0.289); LDL particle diameter andCD36 mRNA levels of resistin mRNA (adjR2=0.192); TG and CD36 mRNA of CAP1mRNA (adjR2=0.376); hsCRP, creatinine and CAP1 mRNA levels of CD36 mRNA,(adjR2=0.505)...
PB  - Универзитет у Београду, Фармацеутски факултет
T2  - Универзитет у Београду
T1  - Određivanje nivoa genske ekspresije rezistina i receptora za rezistin i koncentracije rezistina u krvi pacijenata sa ishemijskom bolesti srca
UR  - https://hdl.handle.net/21.15107/rcub_nardus_9554
ER  - 

@phdthesis{
author = "Munjas, Jelena",
year = "2018",
abstract = "Ishemijska bolest srca (IBS) danas predstavlja jedan od glavnih uzroka smrtnostiu svetu. U osnovi ove bolesti se nalazi ateroskleroza koja predstavlja multifaktorsko,hronično inflamatorno oboljenje indukovano ćelijskim i imunološkim odgovoromvaskularnog zida na metaboličku povredu. Humani rezistin je proinflamatorni protein,koji može imati značajnu ulogu u razvoju ateroskleroze i IBS. Ipak, kliničke studijeizvedene do sada došle su do oprečnih zaključaka vezane za ulogu ovog proteina u IBS.Kako bi se doprinelo boljem razumevanju uloge rezistina u ishemijskoj bolestisrca, ciljevi ovog istraživanja su bili određivanje nivoa iRNK rezistina i njegovogreceptora CAP1 u mononuklearnim ćelijama periferne krvi i koncentracija rezistina ukrvi pacijenata sa IBS i zdravih ispitanika, koji su činili kontrolnu grupu (KG),ispitivanje njihove međusobne povezanosti, povezanosti sa genskom ekspresijom IL-6 iCD36 i povezanosti sa lipidnim i nelipidnim faktorima rizika za razvoj ateroskleroze.U ovu studiju uključeno je 95 pacijenata sa indikacijama za koronarnuangiografiju i 33 ZI. Nivoi iRNK ispitivanih parametara su određeni metodom qPCR-a,koncentracije rezistina ELISA metodom, a subklase lipoproteinskih česticaelektroforezom na gradijentu nedenaturišućeg poliakrilamidnog gela.Koncentracije rezistina, nivoi iRNK CAP1 i CD36 su bili značajno viši kod svihgrupa pacijenata sa IBS u odnosu na KG (p<0,001; p<0,001; p<0,001, redom). Pacijentisa akutnim koronarnim sindromom su imali značajno više koncentracije rezistina uodnosu na druge grupe pacijenata (pstabilna angina pektoris=0,028; pbez anginoznih tegoba i značajnestenoze=0,003). Nivoi iRNK rezistina se nisu značajno razlikovali između ispitivanihgrupa. Pacijenti sa sadržajem malih gustih LDL (mgLDL) čestica ≥50% su imaliznačajno više koncentracije rezistina (p=0,031) i nivoe iRNK rezistina (p=0,004) uodnosu na pacijente sa sadržajem mgLDL čestica <50%. Nezavisni prediktorikoncentracija rezistina su bili kreatinin i ukupni holesterol, adjR2=0,298; nivoa iRNKrezistina dijametar LDL čestica i nivoi iRNK CD36, adjR2=0,192; nivoa iRNK CAP1trigliceridi i nivoi iRNK CD36, adjR2=0,352; nivoa iRNK CD36 hsCRP, kreatinin inivoi iRNK CAP1, adjR2=0,505..., Ischemic heart disease (IHD) is one of the major causes of morbidity and loss ofquality of life across the globe. The pathogenesis of IHD lays in the development ofdyslipidemia, increased proinflammatory processes and consequently atherosclerosisevolvement and progression. Human resistin is a proinflammatory cytokine, with apotential role in atherosclerosis and IHD development. However, clinical studiesconducted so far have been inconsistent regarding resistin’s role in IHD.The aims of this study were to determine resistin mRNA levels and mRNAlevels of resistin receptor, CAP1, in peripheral blood mononuclear cells (PBMC) andcirculating resistin concentrations in IHD patients and healthy subjects (HS), to evaluatetheir interconnection and association with gene expression levels of IL-6 and CD36, aswell as their association with lipid and non-lipid atherosclerosis risk factors.This study included 95 patients requiring coronary angiography and 33 HS.Circulating resistin was measured by ELISA; PBMC resistin mRNA was determined byqPCR. LDL and HDL subclasses were determined by gradient gel electrophoresis.Plasma resistin, CAP1 and CD36 mRNA were significantly higher in all groupsof IHD patients compared to HS (P<0.001; P<0.001; P<0.001, respectively). Acutecoronary syndrome patients had significantly higher plasma resistin compared to othergroups of patients (P=0.028; P=0.003). Resistin mRNA levels were not significantlydifferent between any of the investigated groups. Plasma resistin (P=0.031) and resistinmRNA (P=0.004) were significantly higher in patients with the proportion of sdLDLparticles ≥50%, compared to the group with the relative proportion of sdLDL particles<50%. Multiple linear regression analysis identified creatinine and total cholesterol asindependent predictors of plasma resistin (adjR2=0.289); LDL particle diameter andCD36 mRNA levels of resistin mRNA (adjR2=0.192); TG and CD36 mRNA of CAP1mRNA (adjR2=0.376); hsCRP, creatinine and CAP1 mRNA levels of CD36 mRNA,(adjR2=0.505)...",
publisher = "Универзитет у Београду, Фармацеутски факултет",
journal = "Универзитет у Београду",
title = "Određivanje nivoa genske ekspresije rezistina i receptora za rezistin i koncentracije rezistina u krvi pacijenata sa ishemijskom bolesti srca",
url = "https://hdl.handle.net/21.15107/rcub_nardus_9554"
}

Munjas, J.. (2018). Određivanje nivoa genske ekspresije rezistina i receptora za rezistin i koncentracije rezistina u krvi pacijenata sa ishemijskom bolesti srca. in Универзитет у Београду
Универзитет у Београду, Фармацеутски факултет..
https://hdl.handle.net/21.15107/rcub_nardus_9554

Munjas J. Određivanje nivoa genske ekspresije rezistina i receptora za rezistin i koncentracije rezistina u krvi pacijenata sa ishemijskom bolesti srca. in Универзитет у Београду. 2018;.
https://hdl.handle.net/21.15107/rcub_nardus_9554 .

Munjas, Jelena, "Određivanje nivoa genske ekspresije rezistina i receptora za rezistin i koncentracije rezistina u krvi pacijenata sa ishemijskom bolesti srca" in Универзитет у Београду (2018),
https://hdl.handle.net/21.15107/rcub_nardus_9554 .

TY  - JOUR
AU  - Bogavac-Stanojević, Nataša
AU  - Kotur-Stevuljević, Jelena
AU  - Cerne, Darko
AU  - Zupan, Janja
AU  - Marc, Janja
AU  - Vujić, Zorica
AU  - Crevar-Sakač, Milkica
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Radenković, Miroslav
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3189
AB  - Context: Polyphenols and flavonoids in artichoke leaf tincture (ALT) protect cells against oxidative damage. Objectives: We examined ALT effects on deoxyribonucleic acid (DNA) damage and lipid profiles in rat plasma and gene expression in rat aorta [haemeoxygenase-1 (HO1), haemeoxygenase-2 (HO2), NADPH oxidase 4 (NOX-4), monocyte chemoattractant protein-1 (MCP-1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2)]. Materials and methods: Eighteen male Wistar albino rats were divided into three groups (n=6/group): The control group (CG) was fed with standard pellet chow for 11 weeks; the AD group was fed for a similar period of time with pellet chow supplemented with 2% cholesterol, 3% sunflower oil and 1% sodium cholate. The ADA group was fed with pellet chow (for 1 week), the atherogenic diet (see above) for the following 4 weeks and then with ALT (0.1 mL/kg body weight) and atherogenic diet for 6 weeks. According to HPLC analysis, the isolated main compounds in ALT were chlorogenic acid, caffeic acid, isoquercitrin and rutin. Results: Normalized HO-1 [0.11 (0.04-0.24)] and MCP-1 [0.29 (0.21-0.47)] mRNA levels and DNA scores [12.50 (4.50-36.50)] were significantly lower in the ADA group than in the AD group [0.84 (0.35-2.51)], p = 0.021 for HO-1 [0.85 (0.61-3.45)], p = 0.047 for MCP-1 and [176.5 (66.50-221.25)], p = 0.020 for DNA scores. HO-1 mRNA was lower in the ADA group than in the CG group [0.30 (0.21-0.71), p = 0.049]. Conclusions: Supplementation with ALT limited the effects of the atherogenic diet through reduced MCP-1 expression, thereby preventing oxidative damage.
PB  - Taylor & Francis Ltd, Abingdon
T2  - Pharmaceutical Biology
T1  - The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet
VL  - 56
IS  - 1
SP  - 138
EP  - 144
DO  - 10.1080/13880209.2018.1434549
ER  - 

@article{
author = "Bogavac-Stanojević, Nataša and Kotur-Stevuljević, Jelena and Cerne, Darko and Zupan, Janja and Marc, Janja and Vujić, Zorica and Crevar-Sakač, Milkica and Sopić, Miron and Munjas, Jelena and Radenković, Miroslav and Jelić-Ivanović, Zorana",
year = "2018",
abstract = "Context: Polyphenols and flavonoids in artichoke leaf tincture (ALT) protect cells against oxidative damage. Objectives: We examined ALT effects on deoxyribonucleic acid (DNA) damage and lipid profiles in rat plasma and gene expression in rat aorta [haemeoxygenase-1 (HO1), haemeoxygenase-2 (HO2), NADPH oxidase 4 (NOX-4), monocyte chemoattractant protein-1 (MCP-1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2)]. Materials and methods: Eighteen male Wistar albino rats were divided into three groups (n=6/group): The control group (CG) was fed with standard pellet chow for 11 weeks; the AD group was fed for a similar period of time with pellet chow supplemented with 2% cholesterol, 3% sunflower oil and 1% sodium cholate. The ADA group was fed with pellet chow (for 1 week), the atherogenic diet (see above) for the following 4 weeks and then with ALT (0.1 mL/kg body weight) and atherogenic diet for 6 weeks. According to HPLC analysis, the isolated main compounds in ALT were chlorogenic acid, caffeic acid, isoquercitrin and rutin. Results: Normalized HO-1 [0.11 (0.04-0.24)] and MCP-1 [0.29 (0.21-0.47)] mRNA levels and DNA scores [12.50 (4.50-36.50)] were significantly lower in the ADA group than in the AD group [0.84 (0.35-2.51)], p = 0.021 for HO-1 [0.85 (0.61-3.45)], p = 0.047 for MCP-1 and [176.5 (66.50-221.25)], p = 0.020 for DNA scores. HO-1 mRNA was lower in the ADA group than in the CG group [0.30 (0.21-0.71), p = 0.049]. Conclusions: Supplementation with ALT limited the effects of the atherogenic diet through reduced MCP-1 expression, thereby preventing oxidative damage.",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Pharmaceutical Biology",
title = "The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet",
volume = "56",
number = "1",
pages = "138-144",
doi = "10.1080/13880209.2018.1434549"
}

Bogavac-Stanojević, N., Kotur-Stevuljević, J., Cerne, D., Zupan, J., Marc, J., Vujić, Z., Crevar-Sakač, M., Sopić, M., Munjas, J., Radenković, M.,& Jelić-Ivanović, Z.. (2018). The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. in Pharmaceutical Biology
Taylor & Francis Ltd, Abingdon., 56(1), 138-144.
https://doi.org/10.1080/13880209.2018.1434549

Bogavac-Stanojević N, Kotur-Stevuljević J, Cerne D, Zupan J, Marc J, Vujić Z, Crevar-Sakač M, Sopić M, Munjas J, Radenković M, Jelić-Ivanović Z. The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. in Pharmaceutical Biology. 2018;56(1):138-144.
doi:10.1080/13880209.2018.1434549 .

Bogavac-Stanojević, Nataša, Kotur-Stevuljević, Jelena, Cerne, Darko, Zupan, Janja, Marc, Janja, Vujić, Zorica, Crevar-Sakač, Milkica, Sopić, Miron, Munjas, Jelena, Radenković, Miroslav, Jelić-Ivanović, Zorana, "The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet" in Pharmaceutical Biology, 56, no. 1 (2018):138-144,
https://doi.org/10.1080/13880209.2018.1434549 . .

TY  - JOUR
AU  - Ninić, Ana
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kotur-Stevuljević, Jelena
AU  - Bogavac-Stanojević, Nataša
AU  - Ivanišević, Jasmina
AU  - Simić-Ogrizović, Sanja
AU  - Kravljaca, Milica
AU  - Jelić-Ivanović, Zorana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3060
AB  - Background: Chronic renal failure, particularly end-stage renal disease, is a serious health problem associated with a high mortality rate. Uremic syndrome leads to increased oxidative stress, inflammation, and dyslipidemia. Aims: To examine superoxide dismutase isoenzyme gene expression in peripheral blood mononuclear cells of patients on hemodialysis and to determine the associations between superoxide dismutase isoenzyme gene expression, oxidative stress, and non-enzymatic antioxidative protection. Study Design: Case control study. Methods: This study included 33 patients on hemodialysis (age, 55.33 +/- 15.31 years old) and 33 apparently healthy controls (age, 45.37 +/- 8.92 years old). Superoxide dismutase isoenzyme messenger ribonucleic acid levels were determined by real-time polymerase chain reaction. General biochemical parameters, high sensitivity C-reactive protein, total antioxidant status, thiobarbituric acid-reactive substances, and the superoxide anion radical were also determined. Results: Normalized Cu/Zn superoxide dismutase and Mn superoxide dismutase messenger ribonucleic acid levels were significantly higher in patients than controls (p lt 0.001 and p=0.011). A significant negative correlation was detected between normalized Cu/Zn superoxide dismutase messenger ribonucleic acid levels and total protein total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total antioxidant status. Normalized Mn superoxide dismutase messenger ribonucleic acid levels were negatively correlated with total protein and total antioxidant status. A multiple regression analysis revealed independent associations between total antioxidant status and normalized Cu/Zn superoxide dismutase (p=0.038) and between total antioxidant status and normalized Mn superoxide dismutase messenger ribonucleic acid levels (p=0.038 and p=0.018, respectively). Conclusion: The superoxide dismutase isoenzyme gene is expressed at a higher rate in patients with end-stage renal failure, probably due to increased oxidative stress and attenuated antioxidative defense. The plasma total antioxidant status is an independent predictor of normalized superoxide dismutase isoenzyme messenger ribonucleic acid levels.
PB  - Galenos Yayincilik, Findikzade
T2  - Balkan Medical Journal
T1  - Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease
VL  - 35
IS  - 6
SP  - 431
EP  - 436
DO  - 10.4274/balkanmedj.2018.0170
ER  - 

@article{
author = "Ninić, Ana and Sopić, Miron and Munjas, Jelena and Spasojević-Kalimanovska, Vesna and Kotur-Stevuljević, Jelena and Bogavac-Stanojević, Nataša and Ivanišević, Jasmina and Simić-Ogrizović, Sanja and Kravljaca, Milica and Jelić-Ivanović, Zorana",
year = "2018",
abstract = "Background: Chronic renal failure, particularly end-stage renal disease, is a serious health problem associated with a high mortality rate. Uremic syndrome leads to increased oxidative stress, inflammation, and dyslipidemia. Aims: To examine superoxide dismutase isoenzyme gene expression in peripheral blood mononuclear cells of patients on hemodialysis and to determine the associations between superoxide dismutase isoenzyme gene expression, oxidative stress, and non-enzymatic antioxidative protection. Study Design: Case control study. Methods: This study included 33 patients on hemodialysis (age, 55.33 +/- 15.31 years old) and 33 apparently healthy controls (age, 45.37 +/- 8.92 years old). Superoxide dismutase isoenzyme messenger ribonucleic acid levels were determined by real-time polymerase chain reaction. General biochemical parameters, high sensitivity C-reactive protein, total antioxidant status, thiobarbituric acid-reactive substances, and the superoxide anion radical were also determined. Results: Normalized Cu/Zn superoxide dismutase and Mn superoxide dismutase messenger ribonucleic acid levels were significantly higher in patients than controls (p lt 0.001 and p=0.011). A significant negative correlation was detected between normalized Cu/Zn superoxide dismutase messenger ribonucleic acid levels and total protein total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total antioxidant status. Normalized Mn superoxide dismutase messenger ribonucleic acid levels were negatively correlated with total protein and total antioxidant status. A multiple regression analysis revealed independent associations between total antioxidant status and normalized Cu/Zn superoxide dismutase (p=0.038) and between total antioxidant status and normalized Mn superoxide dismutase messenger ribonucleic acid levels (p=0.038 and p=0.018, respectively). Conclusion: The superoxide dismutase isoenzyme gene is expressed at a higher rate in patients with end-stage renal failure, probably due to increased oxidative stress and attenuated antioxidative defense. The plasma total antioxidant status is an independent predictor of normalized superoxide dismutase isoenzyme messenger ribonucleic acid levels.",
publisher = "Galenos Yayincilik, Findikzade",
journal = "Balkan Medical Journal",
title = "Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease",
volume = "35",
number = "6",
pages = "431-436",
doi = "10.4274/balkanmedj.2018.0170"
}

Ninić, A., Sopić, M., Munjas, J., Spasojević-Kalimanovska, V., Kotur-Stevuljević, J., Bogavac-Stanojević, N., Ivanišević, J., Simić-Ogrizović, S., Kravljaca, M.,& Jelić-Ivanović, Z.. (2018). Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease. in Balkan Medical Journal
Galenos Yayincilik, Findikzade., 35(6), 431-436.
https://doi.org/10.4274/balkanmedj.2018.0170

Ninić A, Sopić M, Munjas J, Spasojević-Kalimanovska V, Kotur-Stevuljević J, Bogavac-Stanojević N, Ivanišević J, Simić-Ogrizović S, Kravljaca M, Jelić-Ivanović Z. Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease. in Balkan Medical Journal. 2018;35(6):431-436.
doi:10.4274/balkanmedj.2018.0170 .

Ninić, Ana, Sopić, Miron, Munjas, Jelena, Spasojević-Kalimanovska, Vesna, Kotur-Stevuljević, Jelena, Bogavac-Stanojević, Nataša, Ivanišević, Jasmina, Simić-Ogrizović, Sanja, Kravljaca, Milica, Jelić-Ivanović, Zorana, "Association Between Superoxide Dismutase Isoenzyme Gene Expression and Total Antioxidant Status in Patients with an End-Stage Renal Disease" in Balkan Medical Journal, 35, no. 6 (2018):431-436,
https://doi.org/10.4274/balkanmedj.2018.0170 . .

TY  - JOUR
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
AU  - Sopić, Miron
AU  - Munjas, Jelena
AU  - Bogavac-Stanojević, Nataša
AU  - Jelić-Ivanović, Zorana
AU  - Kotur-Stevuljević, Jelena
AU  - Spasić, Slavica
AU  - Crevar-Sakač, Milkica
AU  - Milenković, Marina
AU  - Vujić, Zorica
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3054
AB  - Paraoxonases isoenzymes, PON1, PON2 and PON3, have important antioxidative and anti-inflammatory properties in blood and cells. They prevent oxidation of low and high density lipoprotein particles, foam cells formation and development of atherosclerosis. The authors investigated effects of high fat diet and atorvastatin therapy on paraoxonases gene expression levels and distribution in different rat organs. Liver, white adipose tissue (WAT) and aorta were taken from young male Wistar rats that were fed with normal diet (ND), atherogenic diet (AD) and atherogenic diet with 1.14 mg of atorvastatin per kg (ADA). Messenger RNA (mRNA) relative levels of paraoxonase 1 (PON1), paraoxonase 2 (PON2) and paraoxonase 3 (PON3) were measured in rat organs using real-time polymerase chain reaction (PCR). PON1 mRNA expression levels were down-regulated in ADA compared to AD group. ND group had significantly lower PON2 mRNA expression than AD group. PON1 mRNA expression levels were higher in liver than in aorta in group of rats on ND, AD and ADA. PON2 mRNA expression was higher in WAT than in aorta only in ADA group of rats. PON2 and PON3 were significantly higher than PON1 in aorta of rats on each ND, AD or ADA.
PB  - Natl Inst Science Communication-Niscair, New Delhi
T2  - Indian Journal of Biotechnology
T1  - Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy
VL  - 17
IS  - 2
SP  - 217
EP  - 223
UR  - https://hdl.handle.net/21.15107/rcub_farfar_3054
ER  - 

@article{
author = "Ninić, Ana and Spasojević-Kalimanovska, Vesna and Sopić, Miron and Munjas, Jelena and Bogavac-Stanojević, Nataša and Jelić-Ivanović, Zorana and Kotur-Stevuljević, Jelena and Spasić, Slavica and Crevar-Sakač, Milkica and Milenković, Marina and Vujić, Zorica",
year = "2018",
abstract = "Paraoxonases isoenzymes, PON1, PON2 and PON3, have important antioxidative and anti-inflammatory properties in blood and cells. They prevent oxidation of low and high density lipoprotein particles, foam cells formation and development of atherosclerosis. The authors investigated effects of high fat diet and atorvastatin therapy on paraoxonases gene expression levels and distribution in different rat organs. Liver, white adipose tissue (WAT) and aorta were taken from young male Wistar rats that were fed with normal diet (ND), atherogenic diet (AD) and atherogenic diet with 1.14 mg of atorvastatin per kg (ADA). Messenger RNA (mRNA) relative levels of paraoxonase 1 (PON1), paraoxonase 2 (PON2) and paraoxonase 3 (PON3) were measured in rat organs using real-time polymerase chain reaction (PCR). PON1 mRNA expression levels were down-regulated in ADA compared to AD group. ND group had significantly lower PON2 mRNA expression than AD group. PON1 mRNA expression levels were higher in liver than in aorta in group of rats on ND, AD and ADA. PON2 mRNA expression was higher in WAT than in aorta only in ADA group of rats. PON2 and PON3 were significantly higher than PON1 in aorta of rats on each ND, AD or ADA.",
publisher = "Natl Inst Science Communication-Niscair, New Delhi",
journal = "Indian Journal of Biotechnology",
title = "Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy",
volume = "17",
number = "2",
pages = "217-223",
url = "https://hdl.handle.net/21.15107/rcub_farfar_3054"
}

Ninić, A., Spasojević-Kalimanovska, V., Sopić, M., Munjas, J., Bogavac-Stanojević, N., Jelić-Ivanović, Z., Kotur-Stevuljević, J., Spasić, S., Crevar-Sakač, M., Milenković, M.,& Vujić, Z.. (2018). Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy. in Indian Journal of Biotechnology
Natl Inst Science Communication-Niscair, New Delhi., 17(2), 217-223.
https://hdl.handle.net/21.15107/rcub_farfar_3054

Ninić A, Spasojević-Kalimanovska V, Sopić M, Munjas J, Bogavac-Stanojević N, Jelić-Ivanović Z, Kotur-Stevuljević J, Spasić S, Crevar-Sakač M, Milenković M, Vujić Z. Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy. in Indian Journal of Biotechnology. 2018;17(2):217-223.
https://hdl.handle.net/21.15107/rcub_farfar_3054 .

Ninić, Ana, Spasojević-Kalimanovska, Vesna, Sopić, Miron, Munjas, Jelena, Bogavac-Stanojević, Nataša, Jelić-Ivanović, Zorana, Kotur-Stevuljević, Jelena, Spasić, Slavica, Crevar-Sakač, Milkica, Milenković, Marina, Vujić, Zorica, "Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy" in Indian Journal of Biotechnology, 17, no. 2 (2018):217-223,
https://hdl.handle.net/21.15107/rcub_farfar_3054 .

TY  - CONF
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Spasojević-Kalimanovska, Vesna
AU  - Bogavac-Stanojević, Nataša
AU  - Simić-Ogrizović, Sanja
AU  - Kravljaca, Milica
AU  - Jelić-Ivanović, Zorana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2927
PB  - Elsevier Ireland Ltd, Clare
C3  - Atherosclerosis
T1  - Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease
VL  - 263
SP  - e198
EP  - e198
DO  - 10.1016/j.atherosclerosis.2017.06.636
ER  - 

@conference{
author = "Munjas, Jelena and Sopić, Miron and Spasojević-Kalimanovska, Vesna and Bogavac-Stanojević, Nataša and Simić-Ogrizović, Sanja and Kravljaca, Milica and Jelić-Ivanović, Zorana",
year = "2017",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Atherosclerosis",
title = "Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease",
volume = "263",
pages = "e198-e198",
doi = "10.1016/j.atherosclerosis.2017.06.636"
}

Munjas, J., Sopić, M., Spasojević-Kalimanovska, V., Bogavac-Stanojević, N., Simić-Ogrizović, S., Kravljaca, M.,& Jelić-Ivanović, Z.. (2017). Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease. in Atherosclerosis
Elsevier Ireland Ltd, Clare., 263, e198-e198.
https://doi.org/10.1016/j.atherosclerosis.2017.06.636

Munjas J, Sopić M, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Simić-Ogrizović S, Kravljaca M, Jelić-Ivanović Z. Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease. in Atherosclerosis. 2017;263:e198-e198.
doi:10.1016/j.atherosclerosis.2017.06.636 .

Munjas, Jelena, Sopić, Miron, Spasojević-Kalimanovska, Vesna, Bogavac-Stanojević, Nataša, Simić-Ogrizović, Sanja, Kravljaca, Milica, Jelić-Ivanović, Zorana, "Association of peripheral blood mononuclear cells adenylate cyclase-associated protein 1 mRNA with chronic kidney disease" in Atherosclerosis, 263 (2017):e198-e198,
https://doi.org/10.1016/j.atherosclerosis.2017.06.636 . .

TY  - JOUR
AU  - Munjas, Jelena
AU  - Sopić, Miron
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kalimanovska-Oštrić, Dimitra
AU  - Andelković, Kristina
AU  - Jelić-Ivanović, Zorana
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2817
AB  - BackgroundAdenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin. As resistin has been related to CAD development and progression and CAP1 has never been evaluated in CAD, the aim of this study was to determine its peripheral blood mononuclear cells (PBMCs) mRNA in patients with CAD, and resistin plasma concentration, PBMCs resistin and CD36 mRNA, considering resistis ability to stimulate CD36 expression invitro. Materials and methodsThis case-controlled study included 27 healthy subjects (CG) and 66 patients requiring coronary angiography. Of the latter, 42 had nonsignificant CAD whereas 24 had significant CAD. Circulating resistin was measured by ELISA; PBMCs CAP1, resistin and CD36 mRNA were determined by real-time PCR. ResultsPatients with significant as well as patients with nonsignificant CAD had significantly higher resistin concentrations compared to the CG (P lt 0 lt bold> lt /bold>001; P=0 lt bold> lt /bold>003). Resistin mRNA did not show significant difference between the investigated groups. CAP1 and CD36 mRNA were significantly higher in significant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) and nonsignificant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) compared to the CG; significant CAD showed significantly higher CD36 mRNA (P=0 lt bold> lt /bold>040) compared to the nonsignificant CAD group. Multiple linear regression analysis identified Tg and CD36 mRNA as independent predictors of CAP1 (R-2=0 lt bold> lt /bold>402; adjR(2)=0 lt bold> lt /bold>376). ConclusionSignificant up-regulation of PBMCs CAP1, CD36 mRNA and plasma resistin found in significant CAD, as well as in nonsignificant CAD compared to CG, indicates that resistin could be able to exert its effects stronger on cells with up-regulated CAP1 mRNA thus contributing atherosclerosis development.
PB  - Wiley, Hoboken
T2  - European Journal of Clinical Investigation
T1  - Association of adenylate cyclase-associated protein 1 with coronary artery disease
VL  - 47
IS  - 9
SP  - 659
EP  - 666
DO  - 10.1111/eci.12787
ER  - 

@article{
author = "Munjas, Jelena and Sopić, Miron and Spasojević-Kalimanovska, Vesna and Kalimanovska-Oštrić, Dimitra and Andelković, Kristina and Jelić-Ivanović, Zorana",
year = "2017",
abstract = "BackgroundAdenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin. As resistin has been related to CAD development and progression and CAP1 has never been evaluated in CAD, the aim of this study was to determine its peripheral blood mononuclear cells (PBMCs) mRNA in patients with CAD, and resistin plasma concentration, PBMCs resistin and CD36 mRNA, considering resistis ability to stimulate CD36 expression invitro. Materials and methodsThis case-controlled study included 27 healthy subjects (CG) and 66 patients requiring coronary angiography. Of the latter, 42 had nonsignificant CAD whereas 24 had significant CAD. Circulating resistin was measured by ELISA; PBMCs CAP1, resistin and CD36 mRNA were determined by real-time PCR. ResultsPatients with significant as well as patients with nonsignificant CAD had significantly higher resistin concentrations compared to the CG (P lt 0 lt bold> lt /bold>001; P=0 lt bold> lt /bold>003). Resistin mRNA did not show significant difference between the investigated groups. CAP1 and CD36 mRNA were significantly higher in significant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) and nonsignificant CAD (P lt 0 lt bold> lt /bold>001; P lt 0 lt bold> lt /bold>001, respectively) compared to the CG; significant CAD showed significantly higher CD36 mRNA (P=0 lt bold> lt /bold>040) compared to the nonsignificant CAD group. Multiple linear regression analysis identified Tg and CD36 mRNA as independent predictors of CAP1 (R-2=0 lt bold> lt /bold>402; adjR(2)=0 lt bold> lt /bold>376). ConclusionSignificant up-regulation of PBMCs CAP1, CD36 mRNA and plasma resistin found in significant CAD, as well as in nonsignificant CAD compared to CG, indicates that resistin could be able to exert its effects stronger on cells with up-regulated CAP1 mRNA thus contributing atherosclerosis development.",
publisher = "Wiley, Hoboken",
journal = "European Journal of Clinical Investigation",
title = "Association of adenylate cyclase-associated protein 1 with coronary artery disease",
volume = "47",
number = "9",
pages = "659-666",
doi = "10.1111/eci.12787"
}

Munjas, J., Sopić, M., Spasojević-Kalimanovska, V., Kalimanovska-Oštrić, D., Andelković, K.,& Jelić-Ivanović, Z.. (2017). Association of adenylate cyclase-associated protein 1 with coronary artery disease. in European Journal of Clinical Investigation
Wiley, Hoboken., 47(9), 659-666.
https://doi.org/10.1111/eci.12787

Munjas J, Sopić M, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Andelković K, Jelić-Ivanović Z. Association of adenylate cyclase-associated protein 1 with coronary artery disease. in European Journal of Clinical Investigation. 2017;47(9):659-666.
doi:10.1111/eci.12787 .

Munjas, Jelena, Sopić, Miron, Spasojević-Kalimanovska, Vesna, Kalimanovska-Oštrić, Dimitra, Andelković, Kristina, Jelić-Ivanović, Zorana, "Association of adenylate cyclase-associated protein 1 with coronary artery disease" in European Journal of Clinical Investigation, 47, no. 9 (2017):659-666,
https://doi.org/10.1111/eci.12787 . .